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Abstract 31 
Mutations in the Trypanosoma brucei aquaporin AQP2 are associated with resistance to  32 
pentamidine and melarsoprol. We show that TbAQP2 but not TbAQP3 was positively 33 
selected for increased pore size from a common ancestor aquaporin. We demonstrate that 34 
TbAQP2’s unique architecture permits pentamidine permeation through its central pore and 35 
show how specific mutations in highly conserved motifs affect drug permeation. Introduction 36 
of key TbAQP2 amino acids into TbAQP3 renders the latter permeable to pentamidine. 37 
Molecular dynamics demonstrates that permeation by dicationic pentamidine is energetically 38 
favourable in TbAQP2, driven by the membrane potential, although aquaporins are normally 39 
strictly impermeable for ionic species. We also identify the structural determinants that make 40 
pentamidine a permeant but exclude most other diamidine drugs. Our results have wide-41 
ranging implications for optimising antitrypanosomal drugs and averting cross-resistance. 42 
Moreover, these new insights in aquaporin permeation may allow the pharmacological 43 
exploitation of other members of this ubiquitous gene family. 44 
 45 
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Introduction 49 
The Trypanosoma brucei-group species are protozoan parasites that cause severe and fatal 50 
infections in humans (sleeping sickness) and animals (nagana, surra, dourine) (Giordani et al, 51 
2016; Büscher et al, 2017). The treatment is dependent on the sub-species of trypanosome, on 52 
the host, and on the stage of the disease (Giordani et al, 2016; De Koning, 2020). Many anti-53 
protozoal drugs are inherently cytotoxic but derive their selectivity from preferential uptake 54 
by the pathogen rather than the host cell (Munday et al, 2015a; De Koning, 2020). 55 
Conversely, loss of the specific drug transporters is a main cause for drug resistance (Barrett 56 
et al, 2011; Baker et al, 2013; Munday et al, 2015a; De Koning, 2020). This is the case for 57 
almost all clinically used trypanocides, including diamidines such as pentamidine and 58 
diminazene (Carter et al, 1995; De Koning, 2001a; De Koning et al, 2004; Bridges et al, 59 
2007), melaminophenyl arsenicals such as melarsoprol and cymelarsan for cerebral stage 60 
human and animal trypanosomiasis, respectively (Carter & Fairlamb, 1993; Bridges et al, 61 
2007), and the fluorinated amino acid analogue eflornithine for human cerebral 62 
trypanosomiasis (Vincent et al, 2010). The study of transporters is thus important for anti-63 
protozoal drug discovery programmes as well as for the study of drug resistance (Lüscher et 64 
al, 2007; Munday et al, 2015a). 65 
 In Trypanosoma brucei, the phenomenon of melarsoprol-pentamidine cross-resistance 66 
(MPXR) was first described shortly after their introduction (Rollo & Williamson, 1951), and 67 
was linked to reduced uptake rather than shared intracellular target(s) (Frommel & Balber, 68 
1987). The first transporter to be implicated in MPXR was the aminopurine transporter 69 
TbAT1/P2 (Carter & Fairlamb, 1993; Mäser et al, 1999; Munday et al, 2015b) but two 70 
additional transport entities, named High Affinity Pentamidine Transporter (HAPT1) and 71 
Low Affinity Pentamidine Transporter (LAPT1), have been described (De Koning, 2001a; 72 
De Koning & Jarvis, 2001; Bridges et al, 2007). HAPT1 was identified as Aquaglyceroporin 73 
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2 (TbAQP2) via an RNAi library screen, and found to be the main determinant of MPXR 74 
(Baker et al, 2012, 2013; Munday et al, 2014). The apparent permissibility for high molecular 75 
weight substrates by TbAQP2 was attributed to the highly unusual selectivity filter of 76 
TbAQP2, which lacks the canonical aromatic/arginine (ar/R) and full NPA/NPA motifs, 77 
resulting in a much wider pore (Baker et al, 2012; Munday et al, 2014, 2015a). Importantly, 78 
the introduction of TbAQP2 into Leishmania promastigotes greatly sensitised these cells to 79 
pentamidine and melarsen oxide (Munday et al, 2014). Moreover, in several MPXR 80 
laboratory strains of T. brucei the AQP2 gene was either deleted or chimeric after cross-over 81 
with the adjacent TbAQP3 gene, which, unlike AQP2, contains the full, classical ar/R and 82 
NPA/NPA selectivity filter motifs and is unable to transport either pentamidine or 83 
melaminophenyl arsenicals (Munday et al, 2014). Similar chimeric genes and deletions were 84 
subsequently isolated from sleeping sickness patients unresponsive to melarsoprol treatment 85 
(Graf et al, 2013; Pyana Pati et al, 2014) and failed to confer pentamidine sensitivity when 86 
expressed in a tbaqp2-tbaqp3 null T. brucei cell line whereas wild-type TbAQP2 did 87 
(Munday et al, 2014; Graf et al, 2015). 88 
The model of drug uptake through a uniquely permissive aquaglyceroporin (Munday 89 
et al, 2015a) was challenged by a study arguing that instead of traversing the TbAQP2 pore, 90 
pentamidine merely binds to an aspartate residue (Asp265) near the extracellular end of the 91 
pore, above the selectivity filter, followed by endocytosis (Song et al, 2016). This alternative, 92 
‘porin-receptor’ hypothesis deserves careful consideration given that (i) it is an exceptional 93 
assertion that drug-like molecules with molecular weights grossly exceeding those of the 94 
natural substrates, can be taken up by an aquaglyceroporin and (ii) the fact that bloodstream 95 
form trypanosomes do have, in fact, a remarkably high rate of endocytosis (Field & 96 
Carrington, 2009; Zoltner et al, 2016). The question is also important because aquaporins are 97 
found in almost all cell types and the mechanism by which they convey therapeutic agents 98 
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and/or toxins into cells is of high pharmacological and toxicological interest. While TbAQP2 99 
is the first aquaporin described with the potential to transport drug-like molecules, this ability 100 
might not be unique, and the mechanism by which the transport occurs should be carefully 101 
investigated. 102 
We therefore conducted a mutational analysis was undertaken, swapping TbAQP2 103 
and TbAQP3 selectivity filter residues and altering pore width at its cytoplasmic end. This 104 
was complemented with a thorough structure-activity relationship study of the interactions 105 
between pentamidine and TbAQP2, using numerous chemical analogues for which inhibition 106 
constants were determined and interaction energy calculated. The pentamidine-TbAQP2 107 
interactions were further modelled by running a molecular dynamics simulation on a protein-108 
ligand complex, and In addition, we investigated a potential correlation between the T. brucei 109 
endocytosis rate and the rate of pentamidine uptake. Our results unequivocally show that 110 
pentamidine permeates directly through the central pore of TbAQP2 and that uptake is 111 
dependent on the microbial membrane potential. Having identified the essential 112 
characteristics that allow the transport of large, flexible molecules through TbAQP2, this 113 
should now allow the evaluation of aquaporins in other species for similar adaptations.  114 
.CC-BY 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted March 10, 2020. . https://doi.org/10.1101/2020.03.08.982751doi: bioRxiv preprint 
 7
Results 115 
 116 
12. Investigation of the structural determinants of AQP2 for pentamidine transport 117 
1.1. Positive selection for pore size 118 
In T. brucei, the AQP2 and AQP3 genes are arranged as a tandem pair on chromosome 10 119 
and have 74% amino acid identity. Whereas TbAQP2 clearly mediates pentamidine uptake, 120 
TbAQP3 does not (Baker et al, 2012; Munday et al, 2014), nor do various chimeric AQP2/3 121 
rearrangements that give rise to pentamidine resistance (Munday et al, 2014; Graf et al, 122 
2015). To investigate the origin of the AQP2 gene, a phylogenetic analysis of AQPs in 123 
African trypanosomes was performed. The number of aquaporin genes varies: there is a 124 
single aquaporin in T. vivax and T. congolense, two in T. suis and three in T. brucei and its 125 
derivatives (Supplemental Fig. 1A). The most probable tree (Supplemental Fig. 1B) is 126 
consistent with the evolutionary history of the four species (Hutchinson & Gibson, 2015) and 127 
indicates AQP1 as the ancestral AQP present in all trypanosome species. A duplication 128 
occurred in the common ancestor of T. suis and T. brucei after divergence from T. 129 
congolense and a further duplication, to form AQP2 and AQP3, in the ancestor of T. 130 
brucei after divergence from T. suis. Multiple alignment (Supplemental Fig. 1A) shows that 131 
the classical NPA/NPA and ar/R AQP selectivity filter elements are present in all AQPs 132 
except T. brucei AQP2. The divergence of T. brucei AQP2 and 3 was investigated by 133 
calculating the non-synonymous/synonymous codon ratio (dN/dS) for different AQPs 134 
(Supplemental Fig. 1C). For T. brucei aligned with T. suis AQP1, dN/dS is 0.21 and for 135 
AQP3, dN/dS is 0.30 indicating purifying selection. However, comparing T. brucei AQP2 136 
with T. brucei AQP3, dN/dS is 2.0 indicating strong selection pressure for divergence on 137 
AQP2 towards an aquaporin with increased pore size. In order to verify any role of amino 138 
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acids along the TbAQP2 pore in facilitating pentamidine sensitivity and/or uptake, we 139 
performed a mutational analysis. 140 
 141 
1.2 Introduction of AQP3 residues into the AQP2 selectivity filter 142 
One highly conserved motif of aquaporins, believed to be essential for permeant selectivity, 143 
is NPA/NPA which is present in TbAQP3 but not in TbAQP2, where, uniquely, it is 144 
NS131A/NPS263 instead. We therefore constructed a TbAQP2 variant with the classical 145 
NPA/NPA motif (TbAQP2S131P/S263A) and expressed it in the aqp2/aqp3 null cell line (Baker 146 
et al, 2012; Munday et al, 2014). In this cell line, uptake of 30 nM [3H]-pentamidine was 147 
reduced to 4.40 ± 0.71% (n=4) of the rate in the control line expressing TbAQP2WT (P<0.05, 148 
Student’s unpaired t-test), as well as significantly different from the rate measured in parallel 149 
in the tbaqp2/tbaqp3 null cells (P<0.01) (Fig. 1A). The remaining pentamidine uptake was 150 
sufficient to strongly sensitise the TbAQP2S131P/S263A cells to pentamidine in a standard 151 
protocol of 48 h incubation with the drug followed by a further 24 h in the presence of the 152 
resazurin indicator dye (P<0.0001 vs tbaqp2/tbaqp3 null) but the EC50 was still significantly 153 
higher than the TbAQP2WT control (P<0.05) (Fig. 1B). A similar effect was observed for the 154 
melaminophenyl arsenical drug cymelarsan, but there was no change in sensitivity to 155 
diminazene or the control drug phenylarsine oxide (PAO), which is believed to diffuse 156 
directly across the membrane (Fairlamb et al, 1992) (Fig. 1B).  157 
 The mutant L258Y, which has the AQP3 Tyr-250 half of the highly conserved 158 
aromatic/arginine (ar/R) motif, responsible for pore restriction and proton exclusion (Wu et 159 
al, 2009), introduced into the TbAQP2 pore, yielded a drug transport phenotype similar to 160 
TbAQP2S131P/S263A. The [3H]-pentamidine transport rate was reduced to 6.6 ± 1.4% of 161 
TbAQP2WT (P<0.05) but remained above the rate in the tbaqp2/tbaqp3 null cells (P<0.01) 162 
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(Fig. 1A). Pentamidine and cymelarsan EC50 values were also significantly different from 163 
both the TbAQP2WT and the tbaqp2/tbaqp3 null controls (Fig. 1C).  164 
 The ar/R motif is part of the larger selectivity filter, usually WGYR, present in both 165 
TbAQP1 and TbAQP3 but uniquely consisting of I110VL258L264 in TbAQP2 (Baker et al, 166 
2013), all non-polar, open chained residues. Cell lines expressing mutations AQP2I110W and 167 
AQP2L264R, either alone or in combination, displayed pentamidine transport rates, and 168 
pentamidine and cymelarsan EC50 values that were not significantly different from the 169 
tbaqp2/tbaqp3 null controls but highly significantly different from the TbAQP2WT drug-170 
sensitive controls, showing that their capacity for pentamidine and cymelarsan uptake had 171 
been reduced to zero (Fig. 1A, D-F).  172 
We conclude that the unique TbAQP2 replacement of the NPA/NPA motif and all of 173 
the WGYR selectivity filter mutations are necessary for the observed pentamidine and 174 
melaminophenyl arsenical sensitivity observed in cells expressing wild-type TbAQP2. 175 
 176 
1.3 Introduction of TbAQP2 selectivity filter residues into the AQP3 pore enables 177 
pentamidine transport 178 
An interesting question was whether the introduction of (some of) the critical 179 
TbAQP2 residues in TbAQP3 might give the latter the capacity to take up pentamidine. We 180 
therefore constructed TbAQP3W102I/R256L and TbAQP3W102I/R256L/Y250L and tested whether 181 
tbaqp2/tbaqp3 null cells transfected with these mutant aquaporins were able to take up 25 nM 182 
[3H]-pentamidine in the presence of 1 mM adenosine (which blocks uptake via TbAT1/P2). 183 
Pentamidine uptake in the tested cell lines was very low compared to the same cells 184 
expressing TbAQP2WT (Fig. 1G). However, by measuring [3H]-pentamidine uptake over 30 185 
min it was possible to reliably and reproducibly measure radiolabel accumulation in each cell 186 
line. This showed that while uptake in TbAQP3W102I/R256L only trended slightly upwards 187 
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(P>0.05), the mutant AQP3 with all three AQP2 WGYR residues (W102I, R256L and 188 
Y250L) accumulated significantly more [3H]-pentamidine than the tbaqp2/tbaqp3 null cells 189 
(P<0.01) or the null cells expressing TbAQP3WT (P=0.011). This is further corroborated by 190 
comparing the pentamidine sensitivity profile of these cell lines: only TbAQP3W102I/R256L/Y250L 191 
conveyed significant sensitisation to tbaqp2/tbaqp3 null cells (P<0.0001; Fig. 1H). Thus, 192 
TbAQP3 is converted into a pentamidine transporter by the insertion of the AQP2 WGYR 193 
residues, although this does not convey as high a rate of pentamidine uptake as TbAQP2. 194 
 195 
1.4 Mutations of amino acids modelled to potentially bind pentamidine or melarsoprol 196 
dramatically reduce pentamidine transport 197 
Our previous attempts at modelling the binding of pentamidine and melarsoprol into 198 
the pore of TbAQP2 tentatively identified several residues that could be involved in this 199 
process (Munday et al, 2015a), from which we selected two residues, Ile190 and Trp192, at 200 
the extracellular end of the channel (position shown in Fig. 6), to swap with the 201 
corresponding residues of TbAQP3, creating TbAQP2I190T and TbAQP2W192G. Both residues 202 
were predicted to interact with the substrate(s) via main-chain carbonyl oxygen atoms, but the 203 
side chains could nonetheless affect the interactions.  204 
TbAQP2I190T displayed dramatically reduced [3H]-pentamidine uptake, at 2.7 ± 0.7% 205 
(P<0.01, n=4) of the TbAQP2WT control, although significantly higher than the rate of the 206 
tbaqp2/tbaqp3 null negative control (P<0.05) (Fig. 2A). The reduced rate was the result of a 207 
reduced Vmax of the high affinity [3H]-pentamidine uptake, rather than a change in Km; the 208 
LAPT1 Vmax and Km were unchanged in cells expressing TbAQP2I190T or TbAQP2WT 209 
(Supplemental Fig. S2). TbAQP2I190T still conferred some increased pentamidine sensitivity 210 
in the standard resazurin test (P<0.0001), although highly significantly less sensitizing than 211 
TbAQP2WT (P<0.001); an intermediate sensitivity was also observed for cymelarsan (Fig. 212 
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2B). Substitution W192G also produced intermediate sensitivity to both drugs (Fig. 2C) but 213 
the double substitution TbAQP2I190T/W192G displayed no significant pentamidine uptake above  214 
tbaqp2/tbaqp3 null (Fig. 3A) and did not sensitise to pentamidine or cymelarsan (Fig. 2D).  215 
 216 
1.5. The effect of large amino acids at the cytoplasmic end of the pore.  217 
To test whether restrictions at the cytoplasmic end of TbAQP2 would impact on pentamidine 218 
transport, we selected three leucine residues and exchanged each with tryptophan, creating 219 
L84W, L118W and L218W (positions indicated in Fig. 6). Expressing each of the L-to-W 220 
mutants in tbaqp2/tbaqp3 null cells revealed significantly reduced pentamidine sensitivity 221 
compared to the same cells expressing TbAQP2WT (Fig. 3A), while also exhibiting 222 
dramatically reduced rates of [3H]-pentamidine transport (Fig. 3B). This effect was additive, 223 
with TbAQP2L84W/L118W not significantly sensitising for pentamidine and displaying no 224 
detectable increase in [3H]-pentamidine transport relative to tbaqp2/tbaqp3 null cells (Fig. 225 
3A,B). None of these L-to-W mutants sensitised the cells to cymelarsan, diminazene or PAO 226 
(Supplemental Fig. S3). When the same leucine residues were replaced with methionine 227 
instead of tryptophan, variants L84M and L218M were not or barely different from 228 
TbAQP2WT with respect to pentamidine sensitisation (Fig. 3A) or transport (but highly 229 
significantly different from their respective tryptophan variants). For position 118 the Met 230 
replacement had similar effects as the Trp variant had, albeit with a significantly higher rate 231 
of pentamidine transport (1.88 ± 0.20 (n=6) versus 9.38 ± 0.63% (n=3) of TbAQP2WT, 232 
P<0.001; Fig. 3A,B). The L84M and L218M mutants also sensitised to cymelarsan (P<0.01) 233 
and, surprisingly, the L218 W and M mutants also sensitised slightly to diminazene (~2-fold, 234 
P<0.05) (Supplemental Fig. S3).  235 
These results strongly argue that the introduction of large amino acids at the cytosolic 236 
end significantly blocks the transport of pentamidine, whereas the change to LeuMet 237 
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mutants were more permissive for pentamidine, but not cymelarsan. In order to check 238 
whether these variants were still functional aquaglyceroporins, we used the observation of 239 
Jeacock et al, (2017) that T. brucei cells lacking all three AQPs are sensitised to the 240 
Trypanosome Alternative Oxidase inhibitor SHAM, as a result of cellular glycerol 241 
accumulation. By this measure, all of the position 84, 118 and 218 Trp and Met mutants were 242 
able to transport glycerol, as each displayed SHAM EC50 values significantly different from 243 
the tbaqp1-2-3 null cells (Fig. 3C,D); several variants displayed an intermediate SHAM EC50, 244 
being also significantly different from TbAQP2WT, indicating some attenuation of glycerol 245 
efflux capacity for those mutants. Indeed, uptake of [3H]-glycerol closely mirrored the 246 
SHAM observations (Fig. 3E).  247 
 248 
1.6. Overall correlation between [3H]-pentamidine transport rate and pentamidine EC50  249 
The results presented in Figures 2-4 consistently show that even TbAQP2 mutants that 250 
display a large reduction in [3H]-pentamidine uptake rate results can show intermediate 251 
pentamidine sensitivity phenotypes (EC50s), due to the nature of the standard drug sensitivity 252 
test employed, which involves a 48-h incubation with the drug prior to a further 24-h 253 
incubation with resazurin: even a much-reduced transport rate will be sufficient to 254 
accumulate significant amounts of intracellular pentamidine over 3 days. A plot of [3H]-255 
pentamidine transport rates versus pentamidine EC50, using the data for all 19 TbAQP2 and 256 
TbAQP3 mutants for which the transport rates were determined, shows that relatively small 257 
changes in EC50 occur, even with up to approximately 95% reduction in transport rates; at 258 
>95% reduction large EC50 increases become apparent (Supplemental Fig. S4). 259 
 260 
2. Partially blocking endocytosis does not alter the rate of pentamidine transport 261 
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The knockdown of the CRK12 kinase in T. brucei causes a highly reproducible defect in 262 
endocytosis that affects an estimated one third of cells 12 h after RNAi induction and is 263 
ultimately lethal (Monnerat et al, 2013). We utilized this system to investigate whether a link 264 
between endocytosis and pentamidine transport exists. At 12 h of CRK12 RNAi induction 265 
with tetracycline, CRK12 mRNA levels were reduced by 42% (P<0.001) relative to 266 
uninduced controls as determined by qRT-PCR (Fig. 4A). Samples from the culture taken at 267 
this time point showed an increased abundance of cells with swelling characteristic of 268 
endocytosis defects, although this was hard to quantify as a minority of cells were affected, 269 
and to various degrees, as the 12 h time point was deliberately taken as an early point that 270 
would not yet affect cell viability (Supplemental Fig. S5) or cause excessive cellular 271 
pathology. We thus performed parallel uptake experiments with [3H]-pentamidine and [3H]-272 
suramin, with suramin acting as positive control as it is known to enter T. brucei bloodstream 273 
forms through endocytosis after binding to surface protein ISG75 (Zoltner et al, 2016). After 274 
12 h of CRK12 RNAi induction, pentamidine uptake was not significantly less than in the T. 275 
brucei 2T1 parental cells, whereas uptake of [3H]-suramin was (P=0.019, n=5; Fig. 4B,C). 276 
 277 
3. The protonmotive force drives AQP2-mediated pentamidine uptake in bloodstream forms 278 
of T. brucei 279 
It has been reported that knock-down of the HA1–3 plasma membrane proton pumps of T. 280 
brucei (which are essential for maintaining the plasma membrane potential), confers 281 
pentamidine resistance (Alsford et al, 2012; Baker et al, 2013). Interestingly, this locus only 282 
conferred resistance to (dicationic) pentamidine, not to the (neutral) melaminophenyl 283 
arsenicals, unlike knockdown of the TbAQP2/TbAQP3 locus (Alsford et al, 2012). We have 284 
previously reported that the HAPT-mediated pentamidine uptake in T. brucei procyclics 285 
correlates strongly with the proton-motive force (PMF) (De Koning, 2001a). However, it is 286 
.CC-BY 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted March 10, 2020. . https://doi.org/10.1101/2020.03.08.982751doi: bioRxiv preprint 
 14
not clear whether this dependency indicates that pentamidine uptake is mediated by a proton 287 
symporter, as known for many T. brucei nutrient transporters (De Koning & Jarvis, 1997a,b, 288 
1998; De Koning et al, 1998), or reflects the energetics of uptake of cationic pentamidine 289 
being driven by the strong inside-negative membrane potential Vm. The absence of an effect 290 
of HA1–3 knockdown on sensitivity to the neutral melaminophenyl arsenicals strongly argues 291 
against a mechanism of proton symport for HAPT1/AQP2 but a (partial) dependency of 292 
HAPT1/AQP2-mediated uptake of dicationic pentamidine on PMF or Vm would be expected 293 
if the substrate traverses the channel, as opposed to binding a single Asp residue on the 294 
extracellular side of the protein, as suggested in the endocytosis model (Song et al, 2016). 295 
Here we show that the same ionophores that inhibit HAPT1-mediated pentamidine transport 296 
in procyclic cells, and inhibit hypoxanthine uptake in both bloodstream form (BSF) (De 297 
Koning & Jarvis, 1997b) and procyclic (De Koning & Jarvis, 1997a) T. brucei, also dose-298 
dependently inhibit [3H]-pentamidine uptake in BSF (Fig. 5A). This confirms that 299 
pentamidine needs the membrane potential for rapid uptake, as predicted by the dependence 300 
on the HA1–3 proton pumps. Using [3H]-suramin as an endocytosed substrate (Zoltner et al, 301 
2016), we found that 20 µM CCCP also inhibits endocytosis in T. brucei, by 32.6% 302 
(P=0.029; pre-incubation 3 min, plus suramin accumulation over 10 minutes) (Fig. 5B). 303 
While that means that the ionophore experiments do not perfectly discriminate between 304 
endocytosis and trans-channel transport for di-cationic pentamidine, they do for neutral 305 
melaminophenyl arsenicals: the non-dependence of these neutral TbAQP2 substrates on the 306 
proton gradient (Alsford et al, 2012) indicates that, unlike suramin, they are not endocytosed.  307 
Although there is a good correlation between the proton-motive force and TbAQP2-308 
mediated pentamidine transport (Fig. 5C), the effect of CCCP was stronger than expected, 309 
and stronger than previously observed for [3H]-hypoxanthine uptake in T. brucei bloodstream 310 
forms (De Koning & Jarvis 1997b) and we thus investigated whether CCCP might have a 311 
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direct effect on TbAQP2. Indeed, CCCP inhibited uptake of (neutral) [3H]-glycerol in 312 
tbaqp1-2-3 null cells expressing TbAQP2-WT, with an IC50 of 20.7 ± 2.6 µM (n=3) and 313 
inhibited [3H]-pentamidine uptake in the same cells with a similar IC50 (Fig. 5D,E), showing 314 
CCCP to inhibit TbAQP2 directly, irrespective of effects on the membrane potential. 315 
 316 
4. Molecular dynamics modelling of pentamidine interactions with TbAQP2 317 
To further investigate pentamidine binding and permeation in TbAQP2, we used the 318 
coordinates of the TbAQP2-pentamidine complex that was modelled in our previous study 319 
(Munday et al, 2015a). The stability of the protein model was first confirmed by unbiased 320 
atomistic molecular dynamics simulations (Supplemental Fig. S6). We then conducted force-321 
probe simulations, in which a moving spring potential was used to enforce unbinding of 322 
pentamidine from its docked binding position and subsequently reconstructed the free-energy 323 
profile of pentamidine association-dissociation along the pore axis by employing Jarzynski’s 324 
equality (Park et al, 2003). 325 
Figure 6 shows that the docked position of pentamidine correctly identified its 326 
minimum free-energy binding site inside the TbAQP2 pore. Pentamidine adopts an extended 327 
state inside the TbAQP2 pore, adapting its molecular shape to the narrow permeation 328 
channel; pentamidine binding poses display inter-amidine lengths in the range 16.5 – 17 Å. 329 
Importantly, our steered simulations reveal that pentamidine can exit the channel in either 330 
direction, and that unbinding on the route towards the cytoplasm occurs on a free-energy 331 
surface roughly symmetric to that towards the extracellular side. Apart from overcoming the 332 
strongly attractive binding interaction in the centre, there are no major further free-energy 333 
barriers in either direction. The computed free-energy profile of pentamidine binding to the 334 
TbAQP2 structural model slightly overestimates its experimentally recorded binding affinity. 335 
However, the pentamidine conformation binding the narrow pore may not be the lowest-336 
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energy internal conformation of the small molecule, a factor that may be underrepresented in 337 
the profile as simulations were started from the protein-bound state. A further source of 338 
uncertainty stems from the protein model, which is expected to be somewhat less accurate 339 
than a crystal structure. 340 
Due to the dicationic character of pentamidine, the free-energy profile of the molecule 341 
within TbAQP2 strongly depends on the membrane voltage. The voltage drop of -125 mV 342 
across the cytoplasmic membrane of T. b. brucei (De Koning & Jarvis, 1997b), with a 343 
negative potential inside the cell, results in an overall inward attraction of ~22 kJ/mol (Fig. 6, 344 
arrow), i.e. exit from TbAQP2 into the cytoplasm is substantially more favourable for 345 
pentamidine than towards the extracellular side. Taken together, the free-energy profile under 346 
membrane voltage explains the strong coupling between pentamidine uptake and Vm 347 
observed in the experiments. The high affinity of the binding interaction leads to slow off-348 
rates and a relatively low Vmax (0.0044 ± 0.0004 pmol(107 cells)-1s-1) (De Koning, 2001a).  349 
 350 
5. SAR of the pentamidine-AQP2 interaction 351 
In order to study substrate binding and selectivity by the T. b. brucei High Affinity 352 
Pentamidine Transporter (HAPT1/TbAQP2), competition assays were performed with a 353 
series of pentamidine analogues and other potential inhibitors, in the presence of 1 mM 354 
unlabelled adenosine to block diamidine uptake by the TbAT1 aminopurine transporter (De 355 
Koning, 2001a; Bridges et al, 2007). High specific activity [3H]-pentamidine was used at 30 356 
nM, below the Km value (De Koning, 2001a). Uptake was linear for at least 3 min (De 357 
Koning, 2001a) and we utilized 60 s incubations for the determination of inhibition constants 358 
(Ki). At 30 nM [3H]-pentamidine there is virtually no uptake through LAPT1 (Bridges et al, 359 
2007) (Km value ~1000-fold higher than HAPT1) (De Koning, 2001a). The full dataset of 71 360 
compounds is presented in Supplemental Table S1, featuring Kis spanning 5 log units.  361 
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 362 
5.1. The linker length and composition is a strong determinant for high affinity binding of 363 
pentamidine 364 
We determined the Ki values for analogues with a 2–8 methylene unit linker (Fig. 7A, Table 365 
1). Pentamidine analogues featuring 5-7 units displayed submicromolar binding affinities (5 366 
> 6 > 7), while fewer (3-4) or more (8) only conveyed low micromolar binding affinity, 367 
equivalent to a decrease in Gibbs free energy of binding (ΔG0) from 10.2 to 13.0 kJ/mol 368 
(Table 1). Energy minimalization using Gaussian16 yielded an elongated conformation for 369 
pentamidine, with an inter-amidine length of 17.8 Å (Fig. 7B). Replacement of the ether 370 
oxygens with S or NH, analogues RT-48 and RT-50, respectively (Table 1) resulted in 371 
δ(ΔG0) of 10.0 and 12.9 kJ/mol, respectively, indicating that the ether oxygens potentially act 372 
as H-bond acceptors: the NH group serves only as an H-bond donor, as its lone pair is 373 
conjugated with the aromatic system, and the sulphur mimics an aromatic NH (Beno et al, 374 
2015). The sulfone analogue (RT-49), which introduces a dihedral angle of 180° between the 375 
benzamidine and the linker (Brameld et al, 2008), displayed no binding affinity. We propose 376 
that a near-planar conformation of the Phe-O-CH2 segment is required for efficient 377 
engagement of the binding site. This is supported by examining the binding affinities found 378 
for the analogous benzofuramidine series (e.g. RT-14, Fig. 7B), which has a conformationally 379 
predefined ether-methylene bond orientation. Replacement of the middle methylene unit of 380 
pentamidine with an isosteric oxygen (ethylene glycol derivative DB1699, Table 1) results in 381 
a less flexible linker and a remarkable drop in binding affinity (δ(ΔG0) = 15.3 kJ/mol). 382 
 383 
5.2. Two amidine groups are required for high affinity binding  384 
Matched-molecular pair analysis of non-symmetric analogues identified that both amidines 385 
contribute to high affinity binding (compare pairs pentamidine/RT-36 and 386 
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pentamidine/CHI/1/72/1; Table 1). Removal of an H-bond donor (as in CHI/1/72/1) leads to a 387 
loss in ΔG0 >10 kJ/mol. The aniline derivative RT-36 can still act as an H-bond donor, albeit 388 
with significantly reduced basicity (and thus H-bond acceptor propensity), and accordingly 389 
displayed intermediate affinity (δ(ΔG0) = 6.2 kJ/mol). Interestingly, the removal of one 390 
amidine (compare butamidine and CHI/1/69/1) did not produce a significant effect on the 391 
binding affinity (Ki = 3.87 µM and Ki = 2.33 µM, respectively), indicating that the low 392 
affinity of butamidine (compare 36 nM for pentamidine) is due to an inability to attain a 393 
productive interaction with the second amidine. Capping of the amidine group, resulting in 394 
imidazoline analogue RT-32, or methylation (analogue RT-30) reduced binding to HAPT1, 395 
probably due to increased steric crowding at the interaction site, impairing H-bonding. 396 
Reducing pentamidine to just 4-hydroxybenzamidine removed essentially all affinity (Ki = 397 
2.9 mM; δ(ΔG0) = 28.1 kJ/mol), and the replacement of one amidine with a carboxylic group 398 
(compare propamidine, RT-38) was highly deleterious for engagement with the binding site. 399 
Finally, the orientation of the amidine group is crucial as shown by a meta to para change on 400 
the phenyl ring (meta-pentamidine, Table 1). We conclude that for high affinity both amidine 401 
groups must be able to interact unimpeded with the transporter, and in the linear (para) 402 
conformation. 403 
 404 
5.3. Fully conjugated linking units 405 
Stilbamidine and the short-linker analogues FR39 and CRMI8 (Ríos Martínez et al, 406 
2015) displayed low binding affinity (Table 1). Diminazene also displayed similar low 407 
affinity (Ki = 63 µM), and [3H]-diminazene uptake can only just be detected in procyclic T. b. 408 
brucei, i.e. in the absence of the TbAT1/P2 transporter (Teka et al, 2011), potentially 409 
indicating a minimal uptake via HAPT1. Stilbamidine and diminazene feature a similar inter-410 
amidine distance, much shorter than pentamidine (12.35 and 12.25 Å, respectively). DB75 411 
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(furamidine) likewise displayed low affinity (Table 2) and is only internalised by TbAT1/P2 412 
(Ward et al, 2011). The 2,5-furan linker imposes a fixed, inflexible angle of 136º on the 413 
benzamidine moieties and the phenyl rings will adopt a planar orientation with respect to the 414 
furan plane. This appears to allow only one benzamidine end to interact with the transporter, 415 
as (unlike the flexible linker of aliphatic diamidines, vide supra) the replacement of one 416 
amidine group actually increases the binding affinity, presumably by allowing an improved 417 
bonding orientation of the remaining amidine. Thus, DB607 (methoxy for amidine) and 418 
DB960 (N-methyl benzimidazole for benzamidine) display a somewhat higher affinity than 419 
DB75, although the fixed angle was unchanged. Introduction of a pyridine-N in the ortho-420 
position with respect to the amidine functionality (DB994), dramatically reduces the pKa of 421 
the amidine moiety (Wang et al, 2010), resulting in a complete loss of binding affinity (Ki = 422 
167 ± 20 µM), while this was not observed for the corresponding meta-pyridine derivative 423 
(DB829). The unfavourable furan bond angle is further demonstrated by the distally 424 
elongated analogues DB1061 and DB1062 that approximate the inter-amidine distance of 425 
pentamidine but showed no improvement in binding affinity (Table 2). Replacement of furan 426 
with thiazole (ER1004) or methylpyrrole (DB320), which feature a similar bond angle, also 427 
revealed comparable binding affinities. In contrast, a 2,5-substituted thiophene (DB686 and 428 
DB1063) or 2,5-substituted selenophene (DB1213) as a bio-isosteric replacement for the 429 
furan linker resulted in significantly higher binding affinities when compared to their 430 
matched pair analogue (DB1063/DB1061 and DB1213/DB75), which we attribute to a larger 431 
benzamidine-benzamidine angle. This is corroborated by the much weaker binding of the 2,4-432 
thiophene derivative DB1077. A terminal amidine cap (imidazoline) reduced affinity as it did 433 
for pentamidine (compare DB1061/DB1062 and DB1063/DB1064 (Table 2)). A difuran 434 
spacer (DB914) resulted in a high affinity binder (Ki = 0.073 µM) because the two furans 435 
orient themselves in a trans conformation, resulting in a near-linear molecule.  436 
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 437 
5.4. Modifications to the phenyl rings of pentamidine 438 
Substituents in the ortho-position (relative to the alkyloxy substituent) of pentamidine were 439 
poorly tolerated, including chloride or iodide (RT-43, iodopentamidine; Table 1); the amide 440 
analogue displayed no affinity at all (RT-46). Such substituents will cause an out-of-plane 441 
conformation of the alkoxy-group to avoid clashing with the ortho-substituent; high-affinity 442 
pentamidine binding appears to require a coplanar arrangement of the first methylene bound 443 
to the oxygen. Similarly, the introduction of an ortho-pyridine N (RT-52) led to a δ(ΔG0) of 444 
13.7 kJ/mol. This derivative exhibits a conformational bias towards an anti-orientation of the 445 
ether oxygen and pyridine nitrogen (Fig. 7C) (Chein & Corey, 2010). The regio-isomeric 446 
meta-pyridine (RT-53) was completely inactive, reflecting the need for a positively charged 447 
amidine, as this analogue has a significantly reduced pKa (Wang et al, 2010) (see furan-448 
spaced analogue DB994, supra).  449 
 450 
5.5. Non-diamidine trypanocides 451 
The important veterinary trypanocide isometamidium, a hybrid of the phenanthridine 452 
ethidium and the diamidine diminazene, inhibited HAPT1-mediated [3H]-pentamidine uptake 453 
with a Ki of only 3.5 µM (Supplemental Table S1), most probably through an interaction with 454 
its benzamidine moiety, as ethidium displayed virtually no affinity (Ki = 97 µM). However, 455 
we found no evidence that HAPT1/AQP2 is able to transport the bulky isometamidium 456 
molecule. For instance, the 2T1, tbaqp2 null, TbAQP2 expressed in tbaqp2 null, and the 457 
tbaqp2/tbaqp3 null strains displayed statistically identical EC50 values for isometamidium 458 
(112 ± 12 nM, 103 ± 14 nM, 98 ± 24 nM and 95 ± 12 nM, respectively; P>0.05, Student’s 459 
unpaired t-test), and the EC50 values for ethidium were also identical for each of these strains 460 
(1.32 ± 0.07 µM, 1.39 ± 0.08 µM, 1.35 ± 0.11 µM and 1.38 ± 0.14 µM, respectively). It is 461 
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thus likely that isometamidium acts as an extracellular inhibitor rather than a substrate for 462 
HAPT/AQP2, as it does for the TbAT1/P2 transporter (De Koning, 2001b). The nitro-463 
heterocyclic trypanocide megazol (Carvalho et al, 2014), curcumin and its trypanocidal 464 
analogue AS-HK14 (Alkhaldi et al, 2015) failed to inhibit HAPT1. Two trypanocidal bis-465 
phosphonium compounds, CD38 (Taladriz et al, 2012) and AHI43 (Alkhaldi et al, 2016) did 466 
inhibit pentamidine uptake (Ki 5-10 µM), whereas two related compounds, CDIV31 and 467 
AHI15 (Taladriz et al, 2012), did not. Phloretin, which inhibits human AQP9 and AQP3 468 
(Geng et al, 2017),47 displayed a Ki of 1.76 µM for HAPT1/TbAQP2. 469 
 470 
5.6. Are all the HAPT1/AQP2 inhibitors transported? 471 
In an uptake-by-endocytosis model it would be expected that TbAQP2 binding energy 472 
correlates well with TbAQP2-mediated uptake rates for each analogue. We were unable to 473 
ascertain the existence of such a correlation directly, for lack of radiolabelled substrates other 474 
than pentamidine and diminazene and thus used the Resistance Factor (RF; EC50(aqp2/3 475 
null)/EC50(TbAQP2-WT)) as a proxy: clearly, a compound with a significant RF is 476 
internalized by TbAQP2. We observed a poor correlation between HAPT1 binding affinity 477 
and the level of resistance in the tbaqp2/tbaqp3 null strain (r2=0.039, Supplemental Fig. S7; 478 
n=30), with many inhibitors, even those with high affinity, not displaying any significant 479 
resistance in the null line. This indicates that many of these inhibitors inhibit 480 
HAPT1/TbAQP2 but are not transported by it. This is not compatible with a model in which 481 
pentamidine binds and is then internalized by endocytosis: the inhibitors do not show 482 
resistance in the tbaqp2/tbaqp3 null line, whereas substrates do. The caveat inherent to using 483 
the RF instead of rate of transport is that it cannot be excluded that some of the test 484 
compounds are AQP2 substrates yet predominantly taken up by transporters other than 485 
TbAQP2, and hence show a low RF. 486 
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 487 
5.7. SAR summary 488 
Figure 7D summarises the structure-activity relationship of pentamidine interactions with 489 
HAPT1/TbAQP2. No modification in any part of the molecule improved affinity for 490 
TbAQP2, but virtually every modification resulted in a significant loss of binding activity. 491 
The results clearly demonstrate that at least both amidine groups and one or both ether 492 
oxygens are involved in interactions with AQP2, the sum of which adds up to the unusually 493 
high binding energy for this substrate-transporter pair (ΔG0 = -42.6 kJ/mol). These results, 494 
unambiguously demonstrating pentamidine binding in an elongated orientation, are in 495 
complete agreement with the modelling and molecular dynamics, and the mutational analysis 496 
presented above, strengthening those conclusions using a completely different approach. 497 
  498 
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Discussion and conclusion 499 
 500 
There is overwhelming consensus that expression of TbAQP2 is associated with the 501 
extraordinary sensitivity of T. brucei to pentamidine and melaminophenyl arsenicals, and that 502 
mutations and deletions in this locus cause resistance (Baker et al, 2012, 2013; Graf et al, 503 
2013, 2015, 2016; Pyana Pati et al, 2014; Munday et al, 2014, 2015a; Unciti-Broceta et al, 504 
2015). What has remained however unclear is the mechanism underpinning these phenomena 505 
– there are currently no documented other examples of aquaporins transporting such large 506 
molecules.. Yet, considering how ubiquitous aquaporins are to almost all cell types, this 507 
question is of wide pharmacological importance: if large cationic and neutral drugs 508 
(pentamidine and melarsoprol, respectively) can be taken up via an aquaglyceroporin of T. 509 
brucei, what other pharmacological or toxicological roles may these channels be capable of in 510 
other cell types? This manuscript shows clearly that changes in the TbAQP2 WGYR and 511 
NPA/NPA motifs, which collectively enlarge the pore and remove the cation filter, allow the 512 
passage of these drugs into the cell, and thereby underpin the very high sensitivity of the 513 
parasite to these drugs. 514 
 TbAQP2 has evolved, apparently by positive selection given the high dN/dS ratio, to 515 
remove all main constriction points, including the aromatic amino acids and the cationic 516 
arginine of the selectivity filter, and the NPA/NPA motif, resulting in an unprecedentedly 517 
enlarged pore size. Whereas the advantage of this to T. b. brucei is yet unknown, the 518 
adaptation is stable within the brucei group of trypanosomes, and found in T. b. rhodesiense 519 
(Munday et al, 2014; Graf et al, 2016), T. b. gambiense (Graf et al, 2013, 2015; Munday et 520 
al, 2014; Pyana Pati et al, 2014), T. equiperdum and T. evansi (Philippe Büscher and Nick 521 
Van Reet, unpublished). As such, it is not inappropriate to speculate that the wider pore of 522 
TbAQP2 (i) allows the passage of something not transported by TbAQP1 and TbAQP3; (ii) 523 
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that this confers an a yet unknown advantage to the cell; and (iii) that uptake of pentamidine 524 
is a by-product of this adaptation.  525 
 It is difficult to reconcile the literature on pentamidine transport/resistance with 526 
uptake via endocytosis. For instance, the rate of endocytosis in bloodstream trypanosomes is 527 
much higher than in the procyclic lifecycle forms (Langreth & Balber, 1975; Zoltner et al, 528 
2016), yet the rate of HAPT-mediated [3H]-pentamidine uptake in procyclics is ~10-fold 529 
higher than in bloodstream forms (De Koning, 2001a; Teka et al, 2011), despite the level of 530 
TbAQP2 expression being similar in both cases (Siegel et al, 2010; Jensen et al, 2014). 531 
Moreover, in procyclic cells TbAQP2 is spread out over the cell surface (Baker et al, 2012) 532 
but endocytosis happens exclusively in the flagellar pocket (Field & Carrington, 2009) 533 
(which is 3-fold smaller in procyclic than in bloodstream forms (Demmel et al, 2014)), as the 534 
pellicular microtubule networks below the plasma membrane prevent endocytosis (Zoltner et 535 
al, 2016). Similarly, the expression of TbAQP2 in Leishmania mexicana promastigotes 536 
produced a rate of [3H]-pentamidine uptake more than 10-fold higher than observed in T. 537 
brucei BSF (Munday et al, 2014), despite these cells also having a low endocytosis rate 538 
(Langreth & Balber, 1975). The Km and inhibitor profile of the TbAQP2-mediated 539 
pentamidine transport in these promastigotes was indistinguishable from HAPT in procyclic 540 
or bloodstream form T. brucei (De Koning, 2001a). Moreover, the experimental Vmax for 541 
HAPT-mediated pentamidine uptake in T. brucei BSF and procyclics (Baker et al, 2013) can 542 
be expressed as 9.5×105 and 8.5×106 molecules/cell/h, respectively; given a 1:1 stoichiometry 543 
for AQP2:pentamidine the endocytosis model would require the internalisation and recycling 544 
of as many units of TbAQP2 and this seems unlikely, especially in procyclic cells. These 545 
observations are all inconsistent with the contention that pentamidine uptake by 546 
trypanosomes is dependent on endocytosis. 547 
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Furthermore, the Gibbs free energy of -42 kJ/mol for the pentamidine/AQP2 548 
interaction (De Koning, 2001a; Zoltner et al, 2016) is highly unlikely to be the result of the 549 
one interaction between one terminal amidine and Asp265 as required in the endocytosis 550 
model (Song et al, 2016). For the TbAT1 transporter, a double H-bond interaction of Asp140 551 
with the N1(H)/C(6)NH2 motif of adenosine or with one amidine of pentamidine (Munday et 552 
al, 2015b) is estimated to contribute only ~16 kJ/mol to the total ΔG0 of -34.5 kJ/mol for 553 
adenosine (-36.7 kJ/mol, pentamidine) (De Koning & Jarvis, 1999). The endocytosis model 554 
also does not address the internalisation of melaminophenyl arsenicals, which presumably 555 
would equally need access to Asp265. 556 
Here we systematically mapped the interactions between the aquaporin and 557 
pentamidine (ΔG0 for 71 compounds), yielding a completely consistent SAR with multiple 558 
substrate-transporter interactions, summarised in Fig. 7D. The evidence overwhelmingly 559 
supports the notion that pentamidine engages TbAQP2 with both benzamidine groups and 560 
most probably with at least one of the linker oxygens, and that its flexibility and small width 561 
are both required to optimally interact with the protein. This is completely corroborated by 562 
molecular dynamics modelling, which shows minimal energy to be associated with a near-563 
elongated pentamidine centrally in the TbAQP2 pore, without major energy barriers to 564 
exiting in either direction, but driven to the cytoplasmic side by the membrane potential. This 565 
contrasts with the contention (Song et al, 2016) that pentamidine could not be a permeant for 566 
TbAQP2 because it did not transport some small cations and that this proves that the larger 567 
pentamidine cannot be a substrate either. There is scant rationale for that assertion: out of 568 
many possible examples: there are 5 orders of magnitude difference in affinity for 569 
pentamidine and para-hydroxybenzamidine (35 nM vs 2.9 mM; Supplemental Table S1); 570 
adenine is not a substrate for the T. brucei P1 adenosine transporter (De Koning & Jarvis, 571 
1999), the SLC1A4 and SLC1A5 neutral amino acid transporters transport Ala, Ser, Cys and 572 
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Thr but not Gly (Kania et al, 2013), and Na+ is not a permeant of K+ channels (Zhorov & 573 
Tikhonov, 2013). 574 
 The endocytosis model identifies only two key residues for pentamidine access 575 
(Leu264) and binding (Asp265) in TbAQP2 (Song et al, 2016). Yet, multiple clinical isolates 576 
and laboratory strains contain chimeric AQP2/3 genes associated with resistance and/or non-577 
cure that have retained those residues and should thus allow binding and internalisation of 578 
pentamidine (Graf et al, 2013; Pyana Pati, 2014; Unciti Broceta et al, 2015; Munday et al, 579 
2014). Although we find that introduction of the AQP3 Arg residue in position 264 580 
(TbAQP2L264R) disables pentamidine transport, this is because the positively charged 581 
arginine, in the middle of the pore, is blocking the traversing of all cations through the pore, 582 
as is its common function in aquaporins (Beitz et al, 2006; Wu et al, 2009). Indeed, the 583 
W(G)YR filter residues appear to be key determinants for pentamidine transport by AQPs 584 
and the introduction of all three TbAQP2 residues into TbAQP3 (AQP3W102I/R256L/Y250L) was 585 
required to create an AQP3 that at least mildly sensitised to pentamidine, and facilitated a 586 
detectable level of pentamidine uptake. Conversely, any one of the mutations I110W, L258Y 587 
or L264R was sufficient to all but abolish pentamidine transport by TbAQP2. Similarly, the 588 
conserved NPA/NPA motif, and particularly the Asp residues, present in TbAQP3 but 589 
NSA/NPS in TbAQP2, is also associated with blocking the passage of cations (Wree et al, 590 
2011). The unique serine residues in this TbAQP2 motif, halfway down the pore, might be 591 
able to make hydrogen bonds with pentamidine. Reinstating the NPA/NPA motif resulted in a 592 
TbAQP2 variant with a 93.5% reduced rate of [3H]-pentamidine transport. 593 
 Tryptophan residues were introduced towards the cytoplasmic end of the TbAQP2 594 
pore (L84W, L118W, L218W) to test the hypothesis that introducing bulky amino acids in 595 
that position would block the passage of pentamidine. Each of these mutants was associated 596 
with reduced sensitivity to pentamidine and cymelarsan and a >90% reduction in [3H]-597 
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pentamidine uptake. This effect was size-dependent as the pentamidine transport rate of 598 
L84M and L218M was statistically identical to that of control TbAQP2 cells, and L118M 599 
also displayed a higher transport rate than L118W (P<0.0001). These mutant AQPs were still 600 
functional aquaglyceroporins as their expression in tbaqp1-2-3 null cells made those cells less 601 
sensitive to the TAO inhibitor SHAM, and increased glycerol uptake.  602 
Independence from endocytosis was demonstrated by employing the tetracycline-603 
inducible CRK12 RNAi cell line previously described to give a highly reproducible and 604 
progressive endocytosis defect in T. brucei (Monnerat et al, 2013), and unambiguously 605 
distinguishes between uptake via endocytosis and transporters. Twelve hours after CRK12 606 
RNAi induction pentamidine transport was not significantly reduced although uptake of [3H]-607 
suramin, which is accumulated by endocytosis through the T. brucei flagellar pocket (Zoltner 608 
et al, 2016), was reduced by 33% (P=0.0027), indicating successful timing of the experiment 609 
to the early stage of endocytosis slow-down. Although several ionophores, including CCCP, 610 
nigericin and gramicidin strongly inhibited pentamidine uptake, similar to what has been 611 
previously reported for transport processes in T. brucei that are linked to the protonmotive 612 
force (De Koning & Jarvis, 1997a,b, 1998; De Koning et al, 1998), this is probably due to the 613 
inside-negative membrane potential of -125 mV (De Koning & Jarvis, 1997b) attracting the 614 
dicationic pentamidine. This is consistent with the prediction of the molecular dynamics 615 
modelling, and the reported role of the HA1–3 proton pumps in pentamidine but not 616 
melarsoprol resistance (Alsford et al, 2012; Baker et al, 2013). 617 
Altogether, we conclude that the primary entry of the sleeping sickness drugs 618 
pentamidine and melarsoprol into T. brucei spp. is through the unusually large pore of 619 
TbAQP2, rendering the parasite extraordinarily sensitive to the drugs (compare Leishmania 620 
mexicana (Munday et al, 2014)). This is the first report providing detailed mechanistic 621 
evidence of the uptake of organic drugs (of MW 340 and 398, respectively) by an aquaporin. 622 
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We show that this porin has evolved through positive selection and identify the adaptations in 623 
the constriction motifs that enabled it. We consider that other pore-opening adaptations may 624 
have evolved in other organisms, including pathogens, which could initiate the 625 
pharmacological exploitation of aquaporins and lead to the design of new drug delivery 626 
strategies. 627 
 628 
  629 
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Materials and Methods 630 
 631 
Trypanosome strains and cultures.  632 
The drug-sensitive clonal T. b. brucei strain 427 (MiTat 1.2/BS221) (De Koning et al, 2000) 633 
was used for all the work on the SAR of pentamidine transport. The tbaqp2/tbaqp3 null cells 634 
(Baker et al, 2012) and tbaqp1-2-3 null cells (Jeacock et al, 2017) (both obtained from David 635 
Horn, University of Dundee, UK) are derived from the 2T1 strain of T. b. brucei (Alsford & 636 
Horn, 2008). The CRK12 RNAi cell line28 was obtained from Dr Tansy Hammarton 637 
(University of Glasgow, UK) and is also based on the 2T1 cell line; RNAi expression was 638 
induced with 1 µg/ml tetracycline in the medium. All experiments were performed with 639 
bloodstream form trypanosomes grown in vitro in HMI-11 medium as described (Wallace et 640 
al, 2002) at 37 °C in a 5% CO2 atmosphere. Cultures were routinely maintained in 10 ml of 641 
this medium, being seeded at 5×104 cells/ml and passed to fresh medium at reaching 642 
approximately 3×106 cells/ml after 48 h. For transport experiments 150 or 200 ml of culture 643 
was seeded at the same density in large flasks and incubated until the culture reached late-log 644 
phase. 645 
 646 
Materials 647 
A complete list of diamidine analogues and other chemicals used for the SAR study is given 648 
as a table in the supplemental materials with their sources (Supplemental Table S1). 649 
Ionophores and uncouplers nigericin, gramicidin, carbonyl cyanide m-chlorophenyl 650 
hydrazone (CCCP) and valinomycin, as well as the T. brucei proton pump inhibitor N-651 
ethylmaleimide (NEM) were all purchased from Sigma-Aldrich. New compounds synthesised 652 
for this study are listed and described in the Supplemental Materials. 653 
 654 
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Transport of [3H]-pentamidine - Transport of [3H]-pentamidine was performed exactly as 655 
previously described for various permeants (Wallace et al, 2002; Bridges et al, 2007; Teka et 656 
al, 2011) in a defined assay buffer (AB; 33 mM HEPES, 98 mM NaCl, 4.6 mM KCl, 0.55 657 
mM CaCl2, 0.07 mM MgSO4, 5.8 mM NaH2PO4, 0.3 mM MgCl2, 23 mM NaHCO3, 14 mM 658 
glucose, pH 7.3). [3H]-pentamidine was custom-made by GE Healthcare Life Sciences 659 
(Cardiff, UK) with a specific activity of 88 Ci/mmol. Incubations of bloodstream form 660 
trypanosomes with 30 nM of this label (unless otherwise indicated) were performed in AB at 661 
room temperature for 60 s (unless otherwise indicated) and terminated by addition of 1 ml 662 
ice-cold ‘stop’ solution (1 mM unlabelled pentamidine (Sigma) in AB) and immediate 663 
centrifugation through oil (7:1 dibutylphthalate:mineral oil v/v (both from Sigma)). Transport 664 
was assessed in the presence of 1 mM adenosine to block uptake through the P2 aminopurine 665 
transporter; adenosine does not affect HAPT1-mediated transport (De Koning, 2001a; 666 
Bridges et al, 2007). Inhibition assays were performed routinely with 6 - 10 different 667 
concentrations of inhibitor over the relevant range, diluting stepwise by one third each time, 668 
in order to obtain a well-defined and accurate sigmoid plot and IC50 value (inhibitor 669 
concentration giving 50% inhibition of pentamidine transport; calculated by non-linear 670 
regression using Prism 6.0 (GraphPad), using the equation for a sigmoid curve with variable 671 
slope). Highest concentration was usually 1 mM unless this was shown to be insufficient for 672 
good inhibition, or when limited by solubility. Ki values were obtained from IC50 values 673 
using  674 
Ki = IC50/[1 + (L + Km)]        (Eq. 1) 675 
in which L is the [3H]-pentamidine concentration and Km the Michaelis-Menten constant for 676 
pentamidine uptake by HAPT1 (Wallace et al, 2002). The Gibbs Free energy of interaction 677 
ΔG0 was calculated from 678 
ΔG0 = -RTlnKi         (Eq. 2) 679 
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in which R is the gas constant and T is the absolute temperature (Wallace et al, 2002). 680 
 681 
Construction of AQP mutants and transfection 682 
All mutations in the TbAQP2 and TbAQP3 genes were introduced to the relevant backbone 683 
WT vector, either pRPaGFP-AQP2 or pRPaGFP-AQP3 (Baker et al, 2012), by site-directed 684 
mutagenesis. For mutations S131P, S263A, I110W, L264R, L258Y, I190T and W192G in 685 
AQP2, and W102I, R256L and Y250L in AQP3 mutations were inserted using the 686 
QuikChange II kit (Agilent, Santa Clara, CA, USA), following the manufacturer's 687 
instructions. For mutations L84W, L118W, L218W, L84M, L118M and L218M were 688 
introduced using the Q5 Site-Directed Mutagenesis Kit (E0554S), (New England BioLabs) 689 
according to manufacturer’s instructions. 690 
The following primer pairs (itemised in Supplemental Table S2) were used to insert 691 
the named TbAQP2 mutations: for S131P, primers HDK1062 and HDK1063; in combination 692 
with mutation S263A, using primers HDK1064 and HDK1065 to produce plasmid 693 
pHDK166. For I110W, primers HDK607 and HDK608, to produce pHDK84; for L264R, 694 
primers HDK609 and HDK610 to produce pHDK167; the combination I110W/L264R was 695 
produced using primers HDK609 and HDK610 on plasmid pHDK84 to give plasmid 696 
pHDK78; for L258Y, primers HDK1109 and HDK1110 to produce pHDK168; for I190T, 697 
primers HDK1056 and HDK1057 to produce pHDK163; for W192G, primers HDK1058 and 698 
HDK1059 to produce pHDK164; the combination I190T/W192G was produced using 699 
primers HDK1060 and HDK1061 on plasmid pHDK163 to give plasmid pHDK165; for 700 
L84W, primers HDK1276 and HDK1277, producing pHDK210; for L118W, primers 701 
HDK1274 and HDK1275, producing pHDK208; for L218W, primers HDK1272 and 702 
HDK1273, producing pHDK209; for the combination L84W/L118W, primers HDK1276 and 703 
HDK1277 on template pHDK208, producing pHDK227; for L84M, primers HDK1364 and 704 
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HDK1367, producing pHDK234; for L118M, primers HDK1365 and HDK1367, producing 705 
pHDK235; and for L218M, primers HDK1366 and HDK1367, producing pHDK236. To 706 
insert the named mutations into TbAQP3, the following primers were used (Supplemental 707 
Table S3): for W102I, primers HDK511 and HDK512, in combination with mutation R256L, 708 
with primers HDK513 and HDK514, to produce plasmid pHDK71; and to add mutation 709 
Y250L to this combination, primers HDK795 and HDK796, to produce pHDK121. All 710 
plasmids were checked by Sanger Sequencing (Source BioScience, Nottingham, UK) for the 711 
presence of the correct mutation(s) and the cassette for integration digested out with AscI 712 
(NEB, Hitchin, UK) prior to transfection. 713 
 For transfection, 10 µg of digested plasmid and 1-2×107 parasites of the desired cell 714 
line (either aqp2/aqp3 null or aqp1/aqp2/aqp3 null) were resuspended in transfection buffer 715 
and transfected using an Amaxa Nucleofector, with program X-001. After a recovery period 716 
(8-16 h) in HMI-11 at 37 °C and 5% CO2, the parasites were cloned out by limiting dilution 717 
with the selection antibiotic (2.5 µg/ml hygromycin). In all cases the correct integration of the 718 
expression cassettes was analysed by PCR. 719 
 720 
Drug sensitivity assays 721 
Drug sensitivity assays for T. b. brucei bloodstream forms used the cell viability dye 722 
resazurin (Sigma) and were performed exactly as described (Wallace et al, 2002; Bridges et 723 
al, 2007) in 96-well plates with doubling dilutions of test compound, starting at 100 µM, over 724 
2 rows of the plate (23 dilutions plus no-drug control). Incubation time with test compound 725 
was 48 h (37 ºC/5% CO2), followed by an additional 24 h in the presence of the dye. 726 
 727 
Molecular dynamics 728 
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Molecular dynamics simulations were performed using the GROMACS software package, 729 
version 5.1.1 (Abraham et al, 2015). We used the coordinates from the homology model of 730 
TbAQP2 published in Figure 2A in Munday et al (2015a), which was inserted into 731 
POPC/POPE (4:1) membranes, approximately reflecting the membrane composition of T. b. 732 
brucei (Smith & Bütikofer, 2010). The membrane models were constructed using the 733 
CHARMM-GUI webserver (Jo et al, 2008). Subsequently, extended stability tests of the 734 
modelled structure and the bound pentamidine were carried out using unbiased simulations of 735 
100 ns length. The root-mean-square deviation (RMSD) of the protein remained relatively 736 
low with a backbone RMSD converging to ~3 Å after 100 ns simulated time (Supplemental 737 
Fig. S6) bound to the binding site defined previously using molecular docking (Fig. 6) 738 
(Munday et al, 2015a). For these and all following simulations, we used the CHARMM36 739 
force field (Klauda et al, 2010); pentamidine was parameterised using the CHARMM 740 
generalized force field approach (CHGenFF (Vanommeslaeghe et al, 2010)). All simulations 741 
employed a time step of 2 fs under an NPT ensemble at p = 1 bar and T = 310 K. To obtain 742 
non-equilibrium work values for removing pentamidine from the internal AQP2 binding site, 743 
we then conducted steered MD simulations with a probe speed of 0.005 nm/ns and a 744 
harmonic force constant of 300 kJ/mol nm2, pulling pentamidine in both directions along the 745 
pore axis. The free energy profile of pentamidine binding to the AQP2 pore was 746 
reconstructed by using the Jarzynski equality (Jarzynski, 1997). 747 
 748 
Statistical analysis 749 
All transport experiments were performed in triplicate and all values such as rate of uptake, 750 
percent inhibition, Ki, Km, Vmax etc were performed at least three times completely 751 
independently. For drug sensitivity tests, all EC50 values were based on serial dilutions over 752 
two rows of a 96-well plate (23 doubling dilutions plus no-drug control), which were 753 
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obtained independently at least three times. EC50 and IC50 values were determined by non-754 
linear regression using the equation for a sigmoid curve with variable slope and are presented 755 
as average ± SEM. Statistical significance between any two data points was determined using 756 
Student’s t-test (unpaired, two-tailed).  757 
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Figures and Legends 1021 
 1022 
Fig. 1. The selectivity filter differences between TbAQP2 and TbAQP3 are largely 1023 
responsible for their differences in pentamidine sensitivity and transport rates.  1024 
(A) Transport of 30 nM [3H]-pentamidine by tbaqp2/aqp3 null cells expressing TbAQP2-WT 1025 
or one of the TbAQP2 mutants as indicated (blue bars). The corresponding brown bars are 1026 
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pentamidine transport in the control tbaqp2/aqp3 null cells assessed in parallel in each 1027 
experiment. Transport was determined in the presence of 1 mM adenosine to block the 1028 
TbAT1/P2 transporter. Bars represent the average and SEM of at least three independent 1029 
experiments, each performed in triplicate. Blue stars: statistical significance comparison, by 1030 
two-tailed unpaired Student’s tests, between the cells expressing TbAQP2WT and mutants; 1031 
red stars: statistical comparison between the AQP2-expressing cells and control cells; NS, not 1032 
significant. (B-F) EC50 values indicated test drugs, expressed as a percentage of the resistant 1033 
control (tbaqp2/tbaqp3 null), against cell lines either expressing the indicated TbAQP2 1034 
mutant or TbAQP2WT (sensitive control). Red stars and green stars: comparison with 1035 
tbaqp2/aqp3 null or TbAQP2WT-expressing cells, respectively, which were always assessed 1036 
in parallel in each experiment. (G) Transport of 30 nM [3H]-pentamidine by tbaqp2/aqp3 null 1037 
cells expressing TbAQP3 or an AQP3 mutant as indicated. (H) EC50 values of the indicated 1038 
drugs against tbaqp2/aqp3 null cells expressing either TbAQP3 or a mutant thereof, 1039 
expressed as percentage of tbaqp2/aqp3 null.  1040 
All experiments are the average and SEM of at least 3 independent experiments. *, P<0.05; 1041 
**, P<0.01; ***, P<0.001, ****, P<0.0001 by unpaired Student’s t-test, two-tailed. 1042 
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 1044 
Fig. 2. Mutational analysis of TbAQP2 residues I190 and W192. (A) Transport of 30 nM 1045 
[3H]-pentamidine by tbaqp2/tbaqp3 null cells or TbAQP2 variants expressed therein. 1046 
Transport was expressed as a percentage of the rate of the AQP2WT control, performed in 1047 
parallel. Blue stars are comparison with TbAQP2WT, red stars, comparison with the 1048 
tbaqp2/tbaqp3 null control. NS, not significant. (B) EC50 values for the indicated drugs 1049 
against tbaqp2/tbaqp3 null cells, and against TbAQP2WT and TbAQP2I190T expressed 1050 
therein; values were expressed as % of the tbaqp2/tbaqp3 null (resistant) control. Red stars, 1051 
comparison with the resistant control; green stars, comparison with the internal sensitive 1052 
control (TbAQP2WT). The assays for all three strains and all three drugs were done 1053 
simultaneously on at least 3 different occasions. (C) As B but for TbAQP2W192G. (D) As B 1054 
but for TbAQP2I190T/W192G. 1055 
*, P<0.05; **, P<0.01; ***, P<0.001, ****, P<0.0001 by unpaired Student’s t-test. 1056 
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 1057 
Fig. 3. Analysis of TbAQP2 variants with a leucine-to-tryptophan or leucine-to-1058 
methionine substitution near the cytoplasmic end of the pore. (A) Pentamidine EC50 1059 
values (nM) for mutant and WT TbAQP2 expressed in tbaqp2/tbaqp3 cells (aqp2-3 null). The 1060 
mutants are either a Trp (dark blue bars) or Met (orange bars) substitution at the indicated 1061 
positions. The resistant control (aqp2-3 null) and sensitive control (AQP2WT) for the 1062 
separate datasets (Trp or Met) are indicated as hatched bars in the same colours. (B) As (A) 1063 
but showing transport of 30 nM [3H]-pentamidine by the same cell lines, expressed as 1064 
percentage of the transport rate in the TbAQP2 control cells. (C) Pentamidine EC50 values for 1065 
the same mutants as in (A) but expressed in the tbaqp1-2-3 null cells, performed in parallel 1066 
with the determination of EC50 values for SHAM, shown in (D). As all cell lines were done 1067 
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simultaneously, the resistant and sensitive strain control values are identical for the Trp and 1068 
Met mutants in this series.  1069 
All bars represent the average and SEM of at least three independent replicates. *, P<0.05; 1070 
**, P<0.01; ***, P<0.001, ****, P<0.0001 by unpaired Student’s t-test; ns, not significant; 1071 
nd, not determined. 1072 
 1073 
 1074 
Fig. 4. Disabling endocytosis does not reduce uptake of pentamidine. (A) qRT-PCR of 1075 
CRK12, normalised to housekeeping gene GPI-8 (n=3). (B) Transport of 0.025 µM [3H]-1076 
Pentamidine measured in control (non-induced) and CRK12 cell after exactly 12 h of 1077 
tetracycline induction; incubation time with label was 30 s. Bar is average and SEM of 5 1078 
independent determinations, each performed in triplicate. NS, not significant by unpaired 1079 
Student’s t-test. (C) As frame B but uptake of 0.25 µM [3H]-suramin over 15 min; average 1080 
and SEM of 5 independent determinations, each in quadruplicate. **, P=0.0027 by Student’s 1081 
unpaired, two-tailed t-test. 1082 
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 1084 
 1085 
Fig. 5. High affinity pentamidine uptake in T. b. brucei is sensitive to ionophores. (A) 1086 
Uptake of 25 nM [3H]-pentamidine in s427WT bloodstream forms was measured in the 1087 
presence of 1 mM adenosine to block the P2 transporter, and in the further presence of 1088 
various ionophores at the indicated concentrations in µM. Incubation with radiolabel was 5 1089 
min after a 3 min pre-incubation with ionophore. Accumulation of radiolabel was expressed 1090 
as a percentage of the control, being a parallel incubation in the absence of any ionophore. 1091 
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Bars represent the average of 3 – 5 independent determinations (each performed in 1092 
quadruplicate) and SEM. (B) Uptake of 0.25 µM [3H]-suramin by T. b. brucei s427WT cells 1093 
over 10 minutes. Cells were incubated in parallel, with or without the presence of 20 µM 1094 
CCCP (plus 3-minute pre-incubation). Saturation of the suramin-receptor interaction was 1095 
demonstrated by including 100 µM unlabelled suramin (blue bars). Bars represent average 1096 
and SEM or three independent experiments, each performed in quadruplicate. (C) Correlation 1097 
plot of pentamidine transport rate versus protonmotive force (PMF), r2 = 0.93, P<0.05 by F-1098 
test. Concentrations in µM are indicated in the frame. CCCP is shown in red and not included 1099 
in the regression analysis. Each data point is the average of 4 or more independent repeats 1100 
performed in quadruplicate. The values for PMF were taken from (De Koning and Jarvis, 1101 
1997b). (D) Uptake of 0.25µM [3H]-glycerol by aqp1/aqp2/aqp3 null cells expressing 1102 
TbAQP2-WT. Dose response with CCCP and pentamidine (PMD), using an incubation time 1103 
of 1 min. The graph shown was performed in triplicate and representative of three 1104 
independent repeats. (E) As C but using 0.025 µM [3H]-pentamidine and 30 s incubations. 1105 
Representative graph in triplicate from 3 independent repeats.  1106 
*, P<0.05; **, P<0.01; ***, P<0.001 by Student’s unpaired t-test. 1107 
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 1109 
 1110 
Fig. 6. Pentamidine binding in TbAQP2 and free-energy profile of permeation (Left). 1111 
Docked conformation of pentamidine (blue) bound to the TbAQP2 (wheat). The protein and 1112 
the ligand were modelled as described.4 The protein pore is shown in grey mesh, and the 1113 
mutated positions described in the text are in magenta. (Right) Free-energy profile G(L) 1114 
(solid blue line) along the pore axis of TbAQP2 (L). The membrane voltage of T. b. brucei 1115 
gives rise to a voltage drop across the membrane (gray dotted line), which alters the free-1116 
energy profile (dashed blue line includes Vm effect) and reduces the free-energy of 1117 
pentamidine exit into the intracellular bulk by ~22 kJ/mol as compared to the extracellular 1118 
side (black arrow). 1119 
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Fig. 7. Correlation between linker chain length and affinity to HAPT1. 1123 
(A) A series of pentamidine analogues with different methylene linker length was tested for 1124 
inhibition of TbAQP2/HAPT1-mediated 25 nM [3H]-pentamidine transport (i.e. in the 1125 
presence of adenosine to block the TbAT1/P2 transporter). The Ki values are listed in Table 1126 
1. All Ki values are shown as average and SEM of 3 or more independent experiments, each 1127 
performed in triplicate. (B) The distance between the amidine carbon atoms in the lowest-1128 
energy conformation was calculated using density functional theory as implemented in 1129 
Spartan ’16 v2.0.7. Geometry optimisations were performed with the wB97XD functional 1130 
and the 6-31G* basis set at the ground state in gas phase. Structures and distances shown 1131 
represent the dication state that is overwhelmingly prevalent in aqueous solution at neutral 1132 
pH. The numbered red data points correspond to the propamidine - octamidine series in frame 1133 
A. (C) Repulsion between free electron pairs (double dots), indicated by curved blue lines for 1134 
RT-52 in the cis-conformation, causing it to exist overwhelmingly in the anti-conformation. 1135 
(D) Overview of SAR observations on the binding preferences of TbAQP2 for pentamidine 1136 
and its analogues. 1137 
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Table 1. Pentamidine analogues with an aliphatic linker 1139 
 1140 
Compound R1 R2 R3 R4 X Y Z 
Ki 
(µM) 
δ(ΔG0) 
PMD 
(kJ/mol)
Ethamidine Am Am H H CH CH -O-(CH2)2-O- >100 >19.7 
Propamidine Am Am H H CH CH -O-(CH2)3-O- 6.63 ± 1.40 13.0 
Butamidine Am Am H H CH CH -O-(CH2)4-O- 3.87 ± 1.38 11.7 
Pentamidine 
(PMD) 
Am Am H H CH CH -O-(CH2)5-O- 
0.036 ± 
0.0006 
-- 
Hexamidine Am Am H H CH CH -O-(CH2)6-O- 
0.058 ± 
0.011 
1.3 
Heptamidine Am Am H H CH CH -O-(CH2)7-O- 
0.123 ± 
0.010 
3.1 
Octamidine Am Am H H CH CH -O-(CH2)8-O- 2.16 ± 0.48 10.2 
RT-48 Am Am H H CH CH -S-(CH2)5-S- 2.01 ± 0.86 10.0 
RT-50 Am Am H H 
CH CH -NH-(CH2)5-
NH- 
6.27 ± 1.30 12.9 
RT-49 Am Am H H 
CH CH -SO2-(CH2)5-
SO2- 
>150 >20.7 
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DB1699 Am Am H H 
CH CH -O-(CH2)2-O-
(CH2)2-O- 
16.6 ± 2.1 15.3 
RT-36 Am NH2 H H CH CH -O-(CH2)5-O- 0.43 ± 0.07 6.2 
CHI/1/72/1 Am CH3 H H CH CH -O-(CH2)5-O- 3.1 ± 0.7 10.7 
CHI/1/69/1 Am H H H CH CH -O-(CH2)4-O- 2.3 ± 0.5 10.4 
RT-38 Am CA H H CH CH -O-(CH2)3-O- NI, 100 >19.7 
meta-PMD H H Am H 
CH CH 
-O-(CH2)5-O- 
2890 ± 
1050 
28.1 
RT-32 Im Im H H CH CH -O-(CH2)5-O- 0.40 ± 0.08 6.0 
RT-30 MeAm MeAm H H CH CH -O-(CH2)5-O- 0.30 ± 0.07 5.3 
Stilbamidine Am Am H H CH CH -CH=CH- 54.8 ± 3.2 18.3 
FR39 G1 G1 H H CH CH -(CH2)2- 41.7 ±15.2 17.6 
CRMI8 G2 G2 H H CH CH -(CH2)2- 52.8 ±12.7 18.1 
RT-43 Am  Am H Cl CH CH -O-(CH2)5-O- 0.51 ± 0.15 6.6 
Iodo-PMD Am  Am H I CH CH -O-(CH2)5-O- 2.15 ± 0.04 8.4 
RT-46 Am  Am H -C(O)NH2 CH CH -O-(CH2)5-O- >100 >19.7 
RT-52 Am Am H H CH N -O-(CH2)5-O- 8.84 ± 0.88 13.7 
RT-53 Am Am H H N CH -O-(CH2)5-O- NI, 250 >22 
Am, amidine; MeAm, Methyl-amidine; Im, imidazole; CA, carboxylic acid; G1, 2-1141 
aminoimidazoline; G2, 1-methoxy-2-aminoimidazoline. PMD, pentamidine, NI, no inhibition 1142 
at the indicated concentration in µM. Ki is the inhibition constant for [3H]-pentamidine 1143 
transport by TbAQP2/HAPT1. δ(ΔG0) PMD is the difference in Gibbs Free Energy of 1144 
interaction of the substrate with TbAQP2 with the same value for pentamidine (PMD). All Ki 1145 
values are the average and SEM of at least 3-4 independent experiments. 1146 
  1147 
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Table 2. Selection of diamidine analogues with aromatic linkers 1148 
 1149 
Compound R1 R2 Ar X Y 
Ki 
(µM) 
δ(ΔG0) 
PMD 
(kJ/mol) 
DB75 Am Am 
 
CH CH 38.2 ± 10.2 17.3 
DB607 Am OCH3  
CH CH 18.1 ± 1.9 15.5 
DB960 Am NMBa 
 
CH CH 16.6 ± 3.5 15.3 
DB994 Am Am 
 
N CH 167 ± 20 21.0 
DB829 Am Am 
 
CH N 39.9 ± 8.0 17.4 
DB1061 EtAm EtAm 
 
CH CH 32.3 ± 6.0 16.9 
DB1062 2MeIm 2MeIm 
 
CH CH 59.6 ± 11.2 18.4 
ER1004 Am Am 
 
CH CH 68.7 ± 16.0 18.8 
DB320 Am Am 
 
CH CH 71.3 ± 12.1 18.9 
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DB686 Gua Gua 
 
CH CH 0.29 ± 0.11 5.2 
DB1063 EtAm EtAm 
 
CH CH 0.40 ± 0.10 6.0 
DB1064 2MeIm 2MeIm 
 
CH CH 3.0 ± 0.82 11.0 
DB1213 Am Am 
 
CH CH 0.72 ± 0.17 7.5 
DB1077 Am Am 
 
CH CH 13.8 ± 3.1 14.8 
DB914 Am Am 
O
O
CH CH
0.073 ± 
0.013 
1.8 
Am, amidine; Im, imidazole; EtAm, ethylamidine; 2MeIm, 2-methylimidazoline; NMB, N-1150 
methyl benzimidazole. aThis compound lacks the second benzene ring and features the 1151 
terminal NMB moiety instead. Ki is the inhibition constant for [3H]-pentamidine transport by 1152 
TbAQP2/HAPT1. δ(ΔG0) PMD is the difference in Gibbs Free Energy of interaction of the 1153 
substrate with TbAQP2 with the same value for pentamidine (PMD). All Ki values are the 1154 
average and SEM of at least 3-4 independent experiments. 1155 
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A. 
 
Tco       MTSPTVPNPMSTVPMTEM----TE-ANGTTNPPIPDAGERTAV---NFDTEQCK-TKEIL 51 
Tbr1      MSD--EKINVHQYPSETDVRGLKARNGGACEVPFEENN-EPIPNRSANPQEKNE--NELV 55 
Tsu1      MSS--EPVNVHRYTAEGDRSGLKDRHGKTCEVCVGDESAAAVPSAVYNPQEQSGDGPEVK 58 
Tsu2      MQN--QPDAMTH-STAVQMV-NKNPEDGTGGADTERSDEMTAP--------TTRTGDAQK 48 
Tbr2      MQS--QPDNVAY-PMELQAV-NKDGT---VEVRVQGNVDNSSN--------ERWDADVQK 45 
Tbr3      MQS--QPDNVAY-PMELQAV-NKDGT---VEVRVQGNDDSS----------------NRK 37 
          * .      :            .                                      
 
Tco       -AGEGEAPHGPMDINYWPLRNLRMDFREYVGEFLGTFVLLFMGNGVVATTLLDNNLGFLS 110 
Tbr1      GDNADNEAHDAVDVNYWAPRQLRLDYRNYMGEFLGTFVLLFMGNGVVATTILDKDLGFLS 115 
Tsu1      AGGGEAEVQNAADVNNWAPRRLRLDYRDYMGEFLGTFVLLFMGNGVVATTMLDDGLGFLS 118 
Tsu2      CETTNTPKEGAGGINYWAPRELRLKYRDYMGELLGTFVLLLMGNGVVATVVVDGKLGFLS 108 
Tbr2      HEVAEAQEKPVGGINFWAPRELRLNYRDYVAEFLGNFVLIYIAKGAVITSLLVPDFGLLG 105 
Tbr3      HEVAEAQEEVPGGINFWAPRELRLNYRDYMGELLGTFVLLFMGNGVVATVIIDGKLGFLS 97 
                  .   .:* *  *.**:.:*:*:.*:**.***: :.:*.* * ::   :*:*. 
 
Tco       ITFGWGIAVTMGLYVSLGTSSGHLNPAVTVANAFFGGFPWKKVPGYIAMQMLGAFVGAAC 170 
Tbr1      ITLGWGIAVTMGLYISLGISCGHLNPAVTLANAVFGCFPWRRVPGYIAAQMLGAFVGAAC 175 
Tsu1      ITLGWGIAVTMGLYISLGTSCGHLNPAVTVANAVFGCFPWKKVAGYIAMQMLGAFVGAAC 178 
Tsu2      ITLGWGIAVTMALYISLGISSGHLNPAVTVGNAVFGDFPWRKVPGYIAAQMFGAFLGAAC 168 
Tbr2      LTIGIGVAVTMALYVSLGISGGHLNSAVTVGNAVFGDFPWRKVPGYIAAQMLGTFLGAAC 165 
Tbr3      ITLGWGIAVTMALYVSLGISSGHLNPAVTVGNAVFGDFPWRKVPGYIAAQMLGAFLGAAC 157 
          :*:* *:****.**:*** * **** ***:.**.** ***::* **** **:*:*:**** 
 
Tco       AYGVYADLLNKKVSDG----EIEDYAGMFSTYPRDGNSLFSCIFGEFICTAMLTFCVCGI 226 
Tbr1      AYGVYADLLKQHSGG-LVGFGDKGFAGMFSTYPREGNRLFYCIFSEFICTAILLFCVGGI 234 
Tsu1      AYGVFADLLKQHSGG-LIPFGDKGFAGMFSTYPRDGNRLFYCIFGEFICTAMLLFCVSGI 237 
Tsu2      AYGVFADLLKEYCGGKLLAFGAKGIAGVFSTYPKEANSVFACVFGEFICTAILLFCVCGI 228 
Tbr2      AYGVFADLLKAHGGGELIAFGEKGIAWVFAMYPAEGNGIFYPIFAELISTAVLLLCVCGI 225 
Tbr3      AYGVFADLLKAHGGGELIAFGEKGTAGVFSTYPRDSNGLFSCIFGEFICTAMLLFCVCGI 217 
          ****:****:   ..       :. * :*: ** :.* :*  :*.*:*.**:* :** ** 
 
Tco       FDTHNAPATGHEPLAVGALVFAIGNNVGYATGYAINPARDFGPRVFSAILYGSTVFTRGD 286 
Tbr1      FDPNNSPAKGHEPLAVGALVFAIGNNIGYASGYAINPARDFGPRVFSAILFGSEVFTTGN 294 
Tsu1      FDANNSPAKGHEPLAVGALVFAIGNNIGYATGYAINPARDFGPRLFSAILFGSEVFTAGN 297 
Tsu2      FDPNNSPAKKHEPLAVGSLIFAIGNNIGYSTGYAMNPARDFAPRVFSALLLGGEVFSHGN 288 
Tbr2      FDPNNSPAKGYETVAIGALVFVMVNNFGLASPLAMNPSLDFGPRVFGAILLGGEVFSHAN 285 
Tbr3      FDPNNSPAKGHEPLAVGALVFAIGNNIGYSTGYAINPARDFGPRVFSSFLYGGKVFSHAN 277 
          ** :*:**. :* :*:*:*:*.: **.* ::  *:**: **.**:*.::* *. **: .: 
 
Tco       YYFWVPLFIPLLGGIFGIILYKYFVPH 313 
Tbr1      YYFWVPLFIPFLGGIFGLFLYKYFVPY 321 
Tsu1      YYFWVPLFIPFLGGIFGLLLYKYFVPH 324 
Tsu2      YYFWVPLFIPFLGAIFGLFLYKYFVPH 315 
Tbr2      YYFWVPLVVPFFGAILGLFLYKYFLPH 312 
Tbr3      YYFWVPLVIPLFGGIFGLFLYKYFVPH 304 
          *******.:*::*.*:*::*****:*: 
 
 
>Tco AQP1 
MTSPTVPNPMSTVPMTEMTEANGTTNPPIPDAGERTAVNFDTEQCKTKEILAGEGEAPHGPMDINYWPLRNLRMD
FREYVGEFLGTFVLLFMGNGVVATTLLDNNLGFLSITFGWGIAVTMGLYVSLGTSSGHLNPAVTVANAFFGGFPW
KKVPGYIAMQMLGAFVGAACAYGVYADLLNKKVSDGEIEDYAGMFSTYPRDGNSLFSCIFGEFICTAMLTFCVCG
IFDTHNAPATGHEPLAVGALVFAIGNNVGYATGYAINPARDFGPRVFSAILYGSTVFTRGDYYFWVPLFIPLLGG
IFGIILYKYFVPH 
 
>Tbr AQP1 
MSDEKINVHQYPSETDVRGLKARNGGACEVPFEENNEPIPNRSANPQEKNENELVGDNADNEAHDAVDVNYWAPR
QLRLDYRNYMGEFLGTFVLLFMGNGVVATTILDKDLGFLSITLGWGIAVTMGLYISLGISCGHLNPAVTLANAVF
GCFPWRRVPGYIAAQMLGAFVGAACAYGVYADLLKQHSGGLVGFGDKGFAGMFSTYPREGNRLFYCIFSEFICTA
ILLFCVGGIFDPNNSPAKGHEPLAVGALVFAIGNNIGYASGYAINPARDFGPRVFSAILFGSEVFTTGNYYFWVP
LFIPFLGGIFGLFLYKYFVPY 
 
>Tbr AQP2 
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MQSQPDNVAYPMELQAVNKDGTVEVRVQGNVDNSSNERWDADVQKHEVAEAQEKPVGGINFWAPRELRLNYRDYV
AEFLGNFVLIYIAKGAVITSLLVPDFGLLGLTIGIGVAVTMALYVSLGISGGHLNSAVTVGNAVFGDFPWRKVPG
YIAAQMLGTFLGAACAYGVFADLLKAHGGGELIAFGEKGIAWVFAMYPAEGNGIFYPIFAELISTAVLLLCVCGI
FDPNNSPAKGYETVAIGALVFVMVNNFGLASPLAMNPSLDFGPRVFGAILLGGEVFSHANYYFWVPLVVPFFGAI
LGLFLYKYFLPH 
 
>Tbr AQP3 
MQSQPDNVAYPMELQAVNKDGTVEVRVQGNDDSSNRKHEVAEAQEEVPGGINFWAPRELRLNYRDYMGELLGTFV
LLFMGNGVVATVIIDGKLGFLSITLGWGIAVTMALYVSLGISSGHLNPAVTVGNAVFGDFPWRKVPGYIAAQMLG
AFLGAACAYGVFADLLKAHGGGELIAFGEKGTAGVFSTYPRDSNGLFSCIFGEFICTAMLLFCVCGIFDPNNSPA
KGHEPLAVGALVFAIGNNIGYSTGYAINPARDFGPRVFSSFLYGGKVFSHANYYFWVPLVIPLFGGIFGLFLYKY
FVPH 
 
>Tsu AQP1 
MSSEPVNVHRYTAEGDRSGLKDRHGKTCEVCVGDESAAAVPSAVYNPQEQSGDGPEVKAGGGEAEVQNAADVNNW
APRRLRLDYRDYMGEFLGTFVLLFMGNGVVATTMLDDGLGFLSITLGWGIAVTMGLYISLGTSCGHLNPAVTVAN
AVFGCFPWKKVAGYIAMQMLGAFVGAACAYGVFADLLKQHSGGLIPFGDKGFAGMFSTYPRDGNRLFYCIFGEFI
CTAMLLFCVSGIFDANNSPAKGHEPLAVGALVFAIGNNIGYATGYAINPARDFGPRLFSAILFGSEVFTAGNYYF
WVPLFIPFLGGIFGLLLYKYFVPH 
 
>Tsu AQP2 
MQNQPDAMTHSTAVQMVNKNPEDGTGGADTERSDEMTAPTTRTGDAQKCETTNTPKEGAGGINYWAPRELRLKYR
DYMGELLGTFVLLLMGNGVVATVVVDGKLGFLSITLGWGIAVTMALYISLGISSGHLNPAVTVGNAVFGDFPWRK
VPGYIAAQMFGAFLGAACAYGVFADLLKEYCGGKLLAFGAKGIAGVFSTYPKEANSVFACVFGEFICTAILLFCV
CGIFDPNNSPAKKHEPLAVGSLIFAIGNNIGYSTGYAMNPARDFAPRVFSALLLGGEVFSHGNYYFWVPLFIPFL
GAIFGLFLYKYFVPH 
 
 
B. 
 
 
 
 
C. 
 
dN/dS 
 
T. brucei AQP1 v T. suis AQP1   0.21 
T. brucei AQP3 v T. suis AQP3  0.30 
T. brucei AQP2 v T. brucei AQP3  2.00 
 
 
 
 
 
 
Figure S1.  
A. Sequence alignment and individual sequences of the T. congolense, T. b. brucei and T. 
suis. The T. brucei and T. congolense sequences were obtained from tritrypDB, T. suis 
sequences  (Kelly S, Gibson W and Carrington M. The genome of Trypanosoma suis. In 
preparation). The alignment was produced with Clustal Omega. The yellow highlighting 
indicates the N-terminus of the sequences used to determine non-synonymous v 
synonymous ratios. 
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B. Phylogenetic tree of these sequences. The tree is a Neighbour-joining tree produced in 
Clustal Omega with the lengths of the horizontals proportional to the differences. 
 
C. The ratio of non-synonymous v synonymous (dN/dS) codon changes calculated for 
selected comparisons between T. brucei and T. suis AQPs. The ratios were calculated using 
a region of high confidence alignments from ~amino acid 60 (highlighted in Supplemental 
Figure 2A) to the C-terminus.  
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Fig. S2. Pentamidine transport analysis for TbAQP2I190T and TbAQP2WT. (A) 
Transport of 30 nM [3H]-pentamidine by tbaqp2/tbaqp3 null cells expressing TbAQP2I190T, 
in the presence of unlabelled pentamidine at the indicated concentrations. Incubation time 
was 15 min, required to ensure sufficient radiolabel for accurate quantification, and uptake 
was linear and through zero over this period. The inhibition data were plotted to a double 
sigmoidal curve (Prism 7.0) with the bottom value fixed at 0. The high affinity component 
displayed an average an IC50 of 30.9 ± 12.2 nM (n=3) and the lower affinity segment could 
be converted to a Michaelis-Menten plot for determination of Km and Vmax (inset), yielding 
an average Km of 59.9 ± 9.1 µM (n=3). The plot shown is one representative experiment in 
triplicate of three independent experiments. (B) Like (A) but with tbaqp2/tbaqp3 null cells 
expressing TbAQP2WT. Incubation time was 20 s (linear phase). The high affinity phase had 
statistically identical EC50 (41 ± 17 nM; P>0.05) as TbAQP2I190T. The inset shows a zoom-in 
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on the low-affinity part of the curve, with the dotted line representing a theoretical sigmoid 
plot for 1 inhibitor, with the upper limit fixed at the value obtained for 10 μM pentamidine. 
The low affinity component was also statistically identical in the two strains (TbAQP2-WT 
Km = 82.7 ± 17.5 µM (n=3; P>0.05)). Note that the amount of [3H]-pentamidine taken up by 
the low affinity component is highly similar for the mutant (A) and control (B) cell lines, at 
approximately 0.0005 pmol(107 cells)-1s-1. Both frames show one representative experiment 
of three repeats, each performed in triplicate. Error bars are SEM, when not shown, fall 
within the symbol. 
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Figure S3. EC50 values for Cymelarsan, diminazene aceturate and phenylarsine oxide (PAO) 
against the tbaqp2-tbaqp3 null cell line. AQP2-WT and various mutant versions thereof 
(indicated) were expressed in this cell line. EC50 values were determined using the alamar 
blue (resazurin) assay. Bars represent  the average and SEM for at least three determinations. 
nd, not done.  
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Strain EC50 Transport rate 
  AVG SEM AVG SEM
2T1 5.52 1.65 21.86 2.34
AQKO 100 0 1.05 0.16
   +AQP2-WT 0.46 0.27 100 0
   +L264R 126.1 10.2 0.91 0.28
   +L258Y 0.5 0.24 5.4 1.6
   +S131P/S263A 1.92 1.53 6.48 1.39
   +I190T/W192G 99.52 16.4 1.27 0.4
   + I190T 6.89 2.28 2.728 0.744
   +AQP2 I110W 118.7 11.0 0.673 0.296
   +AQP3 WT 105.7 12.6 0.48 0.1
   +AQP3 W102I/R256L 83.83 7.7 0.7 0.18
   +AQP3 W102I/Y250L/R256L 31.94 4.25 1.13 0.1
   +L218W 4.4 0.45 6.94 1.58
   +L118W 46.3 3.36 1.83 0.32
   +L84W 31.98 2.08 2.18 0.52
   +L84W/L118W 59.1 3.58 0.97 0.76
   +L84M 0.43 0.09 48.84 4.68
   +L118M 34.24 5.03 9.33 0.63
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   +L218M 0.63 0.34 61.65 11.17
 
Figure S4. Correlation of the EC50 value with the rate of pentamidine transport for all 19 cell 
lines expressing a wild-type or mutant TbAQP2 in the aqp2/3 null T. b. brucei line. All EC50 
values are expressed as percentage of the resistant control, aqp2/3 null transfected with an 
empty vector (no TbAQP2). 2T1 is the parental cell line of the aqp2/3 null. All values are the 
average of at least three independent determinations; the sensitive and resistant control 
cell lines were included in each independent experiment and the percentages taken are 
from the internal control rather than from the grand average over all experiments. 
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Figure S5. Growth Curve of CRK12 RNAi cells in full HMI-9 medium at 37 ºC/5% CO2, in the 
presence or absence of 1 μg/ml tetracycline (tet). Cell counts were performed with a 
haemocytometer and the average of duplicate determinations is shown.  
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Figure S6. Backbone RMSD of the protein inserted into a lipid bilayer showing convergence 
to ~3 Å in a simulation of 100 ns length.  
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HA
PT
 K
m 
or 
Ki 
(M
)
 
AQP2-KO RF Ki value HAPT1 
AVG AVG SEM
pentamidine 9.06  0.036 0.0006
RT12 0.74 14.3 3.6
RT14 1.08 0.061 0.015
RT43 1.33 0.51 0.15
RT52 5.79 8.84 0.88
Diminazene 0.9 63 3
DB75 0.4 38.25 10.2
DB902 0.61 114 34
DB1111 0.2 0.14 0.03
DB1213 0.55 0.72 0.17
DB1225 0.3 0.54 0.25
CHI/1/72/1 0.8 2.6 0.68
RT05 2.07 0.57 0.18
RT13 3.17 16.1 4.9
RT18 2.02 0.26 0.09
RT24 1.31 0.12 0.03
RT26 1.28 0.34 0.07
RT30 1.35 0.3 0.07
RT36 0.9 0.43 0.07
RT44 1.1 16.78 3.93
RT45 2.13 7.52 0.14
RT01 0.97 49 11
RT02 1.08 66 13
RT08 1.41 75 14
RT10 1.33 35.6 13.4
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RT32 1.23 0.4 0.008
RT48 6.97 2.01 0.86
RT50 17.47 6.27 1.3
Isometamidium 0.91 3.5 0.5
Ethidium 1.05  97 17
 
Figure S7. Correlation between the Resistance Factor (RF; EC50(aqp2/3 null)/EC50(TbAQP2-
WT)) and the Ki value for inhibition of the High Affinity Pentamidine Transporter (HAPT1) 
encoded by TbAQP2. The pentamidine value (bold) is the Km determined with radiolabeled 
pentamidine. The table lists the data points shown in the plot. The line was made by linear 
regression (Prism 6.0); correlation coefficient r2 is 0.039. F-test: slope is not significantly 
different from zero (P = 0.29).  
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Supplemental Table S2: primers used for mutations in TbAQP2 
Mutation Primer  Sequence (altered base(s) underlined) Generated Plasmid 
Original 
Template 
S131P/S263A 
S131P: 
HDK1062 CTCCGGTGGCCATCTCAACCCTGCCGTCACCGTTGGCAA 
pHDK166 pRPaGFP-AQP2 
S131P: 
HDK1063 TTGCCAACGGTGACGGCAGGGTTGAGATGGCCACCGGAG 
S263A: 
HDK1064 TCTCCCCTTGCGATGAATCCCGCACTTGATTTCGGTCCCAGGG 
S263A: 
HDK1065 CCCTGGGACCGAAATCAAGTGCGGGATTCATCGCAAGGGGAGA 
I110W HDK607 CTCGGTCTTACGATTGGTTGGGGTGTGGCTGTCACGATG pHDK84 pRPaGFP-AQP2 
HDK608 CATCGTGACAGCCACACCCCAACCAATCGTAAGACCGAG 
L264R 
HDK609 TCTCCCCTTGCGATGAATCCCTCACGTGATTTCGGTCCCAGGGTCTTC 
pHDK167 pRPaGFP-AQP2 
HDK610 GAAGACCCTGGGACCGAAATCACGTGAGGGATTCATCGCAAGGGGAGA 
I110W/L264R 
L264R: 
HDK609 TCTCCCCTTGCGATGAATCCCTCACGTGATTTCGGTCCCAGGGTCTTC pHDK78 pHDK84 L264R: 
HDK610 
GAAGACCCTGGGACCGAAATCACGTGAGGGATTCATCGCAAGGGGAG
A 
L258Y HDK1109 CAACTTCGGCTTAGCGTCTCCCTATGCGATGAATCCCTCACTTGAT pHDK168 pRPaGFP-AQP2 
HDK1110 ATCAAGTGAGGGATTCATCGCATAGGGAGACGCTAAGCCGAAGTTG 
I190T HDK1056 GCCTTCGGTGAAAAGGGGACTGCGTGGGTGTTTGCCATG pHDK163 pRPaGFP-AQP2 
HDK1057 CATGGCAAACACCCACGCAGTCCCCTTTTCACCGAAGGC 
W192G HDK1058 CGGTGAAAAGGGGATTGCGGGGGTGTTTGCCATGTACCC pHDK164 pRPaGFP-AQP2 
HDK1059 GGGTACATGGCAAACACCCCCGCAATCCCCTTTTCACCG 
I190T/W192G 
HDK1060 GCCTTCGGTGAAAAGGGGACTGCGGGGGTGTTTGCCATGTACCC pHDK165 pHDK163 
HDK1061 GGGTACATGGCAAACACCCCCGCAGTCCCCTTTTCACCGAAGGC 
L84W HDK1276 AAACTTCGTCTGGATATATATCGCTAAGGG pHDK210 pRPaGFP-AQP2 
HDK1277 CCCAGAAATTCAGCCACG 
L118W HDK1274 CACCGCAGTGTGGCTGCTCTGTG pHDK208 pRPaGFP-AQP2 
HDK1275 GAAATGAGTTCAGCAAAAATTG 
L218W HDK1272 CACGATGGCTTGGTATGTTTCACTG pHDK209 pRPaGFP-AQP2 
HDK1273 ACAGCCACACCAATACCA 
L84W/L118W HDK1276 AAACTTCGTCTGGATATATATCGCTAAGGG pHDK227 pHDK208 
HDK1277 CCCAGAAATTCAGCCACG 
L84M HDK1364 AAACTTCGTCATGATATATATCGCTAAGG pHDK234 pHDK210
 
 HDK1367 GAAATGAGTTCAGCAAAAATTGGATAAAATATAC 
L118M HDK1365 CACGATGGCTATGTATGTTTCAC pHDK235 pHDK208 
HDK1367 GAAATGAGTTCAGCAAAAATTGGATAAAATATAC 
L218M HDK1366 CACCGCAGTGATGCTGCTCTGTG pHDK236 pHDK209 
HDK1367 GAAATGAGTTCAGCAAAAATTGGATAAAATATAC 
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Supplemental Table S3: primers used for mutations in TbAQP3 
 
  
Mutations Primer  Sequence (altered base(s) underlined) Plasmid Template
W102I/R256L 
W102I: HDK511 CTCAGCATTACGCTTGGTATCGGCATTGCCGTCACGATG 
pHDK71 pRPaGFP-AQP3 
W102I: HDK512 CATCGTGACGGCAATGCCGATACCAAGCGTAATGCTGAG
R256L: HDK513 TACGCAATAAATCCGGCTCTTGACTTCGGTCCCAGGGTC 
R256L: HDK514 GACCCTGGGACCGAAGTCAAGAGCCGGATTTATTGCGTA 
W102I/R256L/Y
250L 
Y250L HDK795 CATCGGTTACTCAACGGGTCTCGCAATAAATCCGGCTCTT pHDK121 pHDK71 
Y250L HDK796 AAGAGCCGGATTTATTGCGAGACCCGTTGAGTAACCGATG
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Chemistry of new compounds from Paul O’Neill laboratory. 
 
1,2-Bis (4-cyanophenoxy) ethane (Ethamidine Precursor) (1a)  1 
 
Sodium (0.16 g, 6.96 mmol) was added portionwise to anhydrous EtOH (4.0 mL) under an 
atmosphere of nitrogen. After dissolution of the sodium pieces, a solution of 4-cyanophenol 
(0.75 g, 6.38 mmol) dissolved in anhydrous EtOH (4.0 mL) was added followed by dropwise 
addition of 1,2-dibromoethane (0.28 mL, 3.19 mmol). The reaction mixture was allowed to 
stir at reflux under a nitrogen atmosphere for 3 days after which the mixture was cooled, 
filtered, the solid washed with water and dried under vacuum. Purification by column 
chromatography eluting with DCM: hexane (8:2) gave the desired dinitrile ethamidine 
precursor (1a) as a white solid (1.42 g, 84%). Mp 211-212°C; 1H NMR (CDCl3, 400MHz) δ 
7.61 (d, 4H, J = 9.0 Hz, ArH), 7.01 (d, 4H, J = 9.0 Hz, ArH), 4.39 (s, 4H, CH2); 13C NMR 
(CDCl3, 100MHz) δ 161.6, 134.1, 118.9, 115.3, 104.7, 66.4; νmax (NujOI) /cm-1 3326 (C-O-C), 
3033 (ArH), 2898 (OH), 2223 (CN), 1602 (Ar), 1509 (Ar), 1247 (C-O-C); m/z (CI) 282 
([M+NH4]+), found 282.12433, C16H16O2N3 requires 282.12424; anal. Found C 72.37, H 4.51, 
N 10.54, C16H12O2N2 requires C 72.71, H 4.57, N 10.60. 
 
4,4'-(ethane-1,2-diylbis(oxy))dibenzimidamide dihydrochloride dihydrate (Ethamidine, 
Compound CHI/1/30/1) (2) 1 
  
 
 
(0.51 g, 1.92 mmol) of 1a was dissolved in a mixture of anhydrous benzene (54 mL) and 
EtOH (2.90 mL), cooled to 0 °C and saturated with HCl gas. The mixture was sealed and 
allowed to stir at room temperature for 3 days after which anhydrous Et2O (28 mL) was 
introduced and the mixture was allowed to stir for 10 minutes. The solids were filtered under 
nitrogen and dissolved in a mixture of anhydrous EtOH (36 mL) and EtOH.NH3 (36 mL). The 
mixture was heated overnight (50 oC), cooled to room temperature and reduced by half in 
vacuo. Ether was added to precipitate the solid which was filtered, washed and dried under 
vacuum. Purification by recrystallisation (2N HCl) gave the desired compound 2 as fine white 
needles (0.54 g, 70%). Mp 333°C; 1H NMR (MeOD, 400MHz) δ 7.85 (d, 4H, J = 9.0 Hz, 
ArH), 7.23 (d, 4H, J = 9.0 Hz, ArH), 4.52 (s, 4H, CH2); 13C NMR (MeOD, 100MHz) δ 167.9, 
165.3, 131.5, 121.7, 116.7, 68.5; νmax (Nujol) /cm-1 3362 (NH), 3037 (ArH), 2940 (C-H), 1658 
(C=N-H), 1606 (Ar), 1505 (Ar), 1245 (C-0-C); m/z (ESP) 299 ([M-H]-); anal. Found C 47.54 H 
5.62 N 14.30, C16H24N4O4Cl2 requires C 47.18, H 5.94, N 13.76. 
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4, 4’-(propane-1,3-diylbis(oxy))dibenzonitrile (Propamidine Precursor) (1b)1 
 
Sodium (0.16 g, 6.96 mmol) was added portionwise to anhydrous EtOH (4.0 mL) with stirring 
under an atmosphere of nitrogen. After dissolution of Na, a solution of 4-cyanophenol (0.75 
g, 6.38 mmol) dissolved in dry ethanol (4.0 mL) was added followed by dropwise addition of 
1,3-dibromopropane (0.32 mL, 3.19 mmol). The reaction mixture was allowed to stir at reflux 
under a nitrogen atmosphere for 3 days after which the mixture was cooled, filtered, the solid 
washed with water and dried under vacuum. Purification by column chromatography eluting 
with DCM: hexane (8:2) gave the desired compound 1b as a white solid (1.40 g, 79%). Mp 
190-191°C; 1H NMR (CDCl3, 400MHz) δ 7.59 (d, 4H, J = 8.5 Hz, ArH), 6.96 (d, 4H, J = 8.5 
Hz, ArH), 4.20 (t, 4H, J = 6.0 Hz, CH2), 2.32 (m, 2H, CH2); 13C NMR (CDCl3, 100MHz) δ 
161.9, 134.0, 119.1, 115.1, 104.2, 64.4, 28.8; νmax (Nujol) /cm-1 3104 (Ar-H), 2823 (C-H), 
2221 (C≡N), 1604 (Ar), 1509 (Ar), 1253 (C-O); m/z (CI) 296 ([M+NH4]+), found 296.14037, 
C17H18N3O2 requires 296.13992; anal. Found C 73.22, H 5.13, N 10.03, C17H14N2O2 requires 
C 73.37, H 5.07, N 10.07. 
 
4,4’-(propane-1,3-diylbis(oxy))dibenzimidamide dihydrochloride dihydrate 
(Propamidine, Compound CHI/1/25/5)  (3)1 
 
(0.50 g, 1.79 mmol) of 1b was dissolved in a mixture of anhydrous benzene (55 mL) and 
anhydrous ethanol (3.0 mL), cooled to 0 oC and saturated with HCl gas. The mixture was 
sealed and allowed to stir at room temperature for 3 days after which ether (30 mL) was 
added and the mixture was allowed to stir for 10 minutes. The solids were filtered under 
nitrogen and dissolved in a mixture of anhydrous EtOH (36 ml) and EtOH.NH3 (36 mL). The 
mixture was heated overnight (50 °C), cooled to room temperature and reduced by half in 
vacuo. Et2O (15 mL) was added to precipitate the solid which was filtered, washed and dried 
under vacuum. Purification by recrystallisation (2N HCl) gave the desired compound 3 as 
fine white needles (0.59 g, 78%). Mp 200°C; 1H NMR (MeOD, 400MHz) δ 7.82 (d, 4H, J = 
9.0 Hz, ArH), 7.19 (d, 4H, J = 9.0 Hz, ArH), 4.34 (t, 4H, J = 6.0 Hz, CH2), 2.46 (m, 2H, CH2); 
13C NMR (MeOD, 100MHz) δ 167.9, 165.5, 131.5, 121.5, 121.4, 116.6, 66.4, 30.3; νmax 
(Nujol) /cm-1 3280 (N-H), 3038 (Ar-H), 2929 (C-H), 1504 (Ar), 1606 (Ar), 1240 (C-O-C); m/z 
(ESP) 313 ([M-H]-); anal. Found C 48.60, H 6.10, N 13.25, C17H26N4O4Cl2 requires C 48.46, 
H 6.22, N 13.30. 
 
4,4’-(Butane-1,4-diylbis(oxy))dibenzonitrile (Butamidine precursor) (1c)1 
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Sodium (0.10 g, 4.35 mmol) was added portionwise to dry EtOH (4.0 mL) stirring under an 
atmosphere of nitrogen. After dissolution of sodium, a solution of 4-cyanophenol (0.47 g, 
3.95 mmol) dissolved in dry ethanol (4.0 mL) was added followed by dropwise addition of 
1,4-dibromobutane (0.24 mL, 1.98 mmol). The reaction mixture was allowed to stir at reflux 
under a nitrogen atmosphere for 3 days after which the mixture was cooled, filtered, the solid 
washed with water and dried under vacuum. Purification by column chromatography eluting 
with DCM: hexane (8:2) gave the desired compound 1c as a white solid (1.03 g, 89%). Mp  
174°C; 'H NMR (CDCI3, 400MHz)  δ 7.59 (d, 4H, J = 8.9 Hz, ArH), 6.93 (d, 4H, J = 8.9 Hz, 
ArH), 4.08 (m, 4H, CH2), 2.01 (m, 4H, CH2); 13C NMR (CDCl3, 100MHz) δ 162,1, 134.0, 
119.1, 115.1, 104.0, 67.7, 25.7; νmax (Nujol) /cm-1 3332 (C-O-C), 3033 (Ar-H). 2956 (C-H), 
2219 (C≡N), 1604 (Ar). 1506 (Ar), 1251 (C-O-C); m/z (CI) 310 ([M+NH4]+) found 310.15532, 
C18H20N3O2 requires 310.15555; anal. Found C 74.03, H 5.55, N 9.55, C18H16N2O2 requires 
73.95, H 5.52, N 9.58. 
 
 
 
4,4’-(Butane-l ,4-diylbis(oxy))dibenzimiamide dihydrochloride dihydrate (Butamidine, 
Compound CHI/1/41/1) (4)1 
 
 
Compound 1c (0.42 g, 1.44 mmol) was dissolved in a mixture of anhydrous benzene (46 
mL) and anhydrous ethanol (2.50 mL), cooled to 0 °C and saturated with HCl gas. The 
mixture was sealed and allowed to stir at room temperature for 3 days after which anhydrous 
Et2O (40 mL) was introduced and the mixture was allowed to stir for 10 minutes. The solids 
were filtered under nitrogen and dissolved in a mixture of anhydrous EtOH (34 mL) and 
EtOH.NH3 (34 mL). The mixture was heated overnight (50 °C), cooled to room temperature 
and reduced by half in vacuo. Ether (15 mL) was added to precipitate the solid which was 
filtered, washed and dried under vacuum. Purification by recrystallisation (2N HCl) gave the 
desired compound 4 as fine white needles (0.46 g, 73%). Mp 286-287°C', ‘H NMR (MeOD, 
400MHz) δ, 7.80 (d, 4H, J = 9.0 Hz, ArH), 7.14 (d, 4H, J = 9.0Hz, ArH), 4.19 (m, 4H, CH2), 
2.02 (m, 4H, CH2); 13 CNMR (MeOD, 100MHz) δ 165.7, 131.4, 121.2, 116.7, 69.7, 27.2; νmax 
(Nujol) /cm-1 3370 (N-H), 3129 (Ar-H), 2884 (C-H), 1650 (C≡N), 1606 (Ar), 1508 (Ar), 1257 
(C-O); m/z (ESP) 327 ([M+H]+); anal. Found C 49.87, H 6.46, N 12.67, C18H28N4O4Cl2 
requires C 49.66, H 6.48, N 12.87. 
   
 4-(4-phenoxybutoxy) benzonitrile   
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Sodium (0.16g, 6.96 mmol) was added dropwise to dry ethanol (5 mL) and dissolved under 
a nitrogen atmosphere.  To this a solution of 4-cyanophenol (0.53g, 4.47 mmol) dissolved in 
anhydrous ethanol (5ml) was added followed by addition of 1,4-dibromobutane (0.53 mL, 
4.47 mmol). The reaction mixture was allowed to stir at reflux and monitored by TLC. After 
consumption of 4-cyanophenol, the reaction mixture was allowed to cool to room 
temperature. In a separate flask sodium (0 16 g, 6.96 mmol) was added portionwise to 
ethanol (5 mL) stirring under nitrogen. A solution of phenol (0.42 g, 4.47 mmol) in ethanol 
(5ml) was added and stirred for 10 minutes. This mixture was added dropwise to the cooled 
mixture and allowed to stir under reflux for 3 days after which the mixture was cooled, 
filtered, the solid washed with water and dried under vacuum. Purification by column 
chromatography eluting with DCM: hexane (8:2) gave the desired compound 4-(4-
phenoxybutoxy) benzonitrile as a white solid (0.98 g, 82%). Mp 130°C; 1H NMR (CDCl3, 
400MHZ) δ 7.57 (d, 2H, J = 8.9 Hz, ArH), 7.28 (d, 1H, J = 7.5 Hz, ArH), 7.26 (d, 1H, J = 8.1 
Hz, ArH), 6.92 (m, 5H, ArH), 4.08 (t, 2H, J = 5.9 Hz, CH2), 4.03 (t, 2H, J = 5.9 Hz, CH2), 1.99 
(m, 4H, CH2); 13C NMR (CDCl3, 100MHz) δ 162.6, 159.2, 134.3, 129.8, 121.1, 115.5, 114.8, 
104.3, 68.3, 67.5, 26.2; νmax (Nujol) /cm-1 3043 (Ar-H), 2884 (C-H), 2219 (C≡N), 1602 (Ar), 
1504 (Ar), 1247 (C-O); m/z (CI) 285 ([M+NH4]+), found 285.16020, C17H21N2O2 requires 
285.16031; anal. Found C 76.40, H 6.46, N 5.44, C17H17NO2 requires C 76.38, H 6.40, N 
5.24. 
 
4-(4-Phenoxybutoxy)benzimidamide hydrochloride hydrate (Compound CHI/1/69/1)  
 
 
4-(4-phenoxybutoxy) benzonitrile (0.27 g, 1.01 mmol) was dissolved in a mixture of 
anhydrous benzene (100 mL) and ethanol (1.60 mL), cooled to 0 °C and saturated with HCl 
gas. The mixture was sealed and allowed to stir at room temperature for 3 days after which 
anhydrous Et2O (16 mL) was introduced and the mixture was allowed to stir for an additional 
10 minutes. The solids were filtered under nitrogen and dissolved in a mixture of anhydrous 
EtOH (20 mL) and anhydrous EtOH.NH3 (20 mL). The mixture was heated overnight (50 oC), 
cooled to room temperature and reduced by half in vacuo. Ether (30 mL) was added to 
precipitate the solid which was filtered, washed and dried under vacuum. Purification by 
recrystallisation (2N HCl) gave the desired compound 4-(4-Phenoxybutoxy)benzimidamide 
hydrochloride hydrate as fine white needles (0.28 g, 82%). Mp 134-135°C; 1H NMR (DMSO, 
400MHz) δ 9.28 (s, 2H, NH;), 9.08 (s, 2H, NHZ), 7.86 (d, 2H, J = 9.0 Hz, ArH), 7.29 (d, 1H, J 
= 7.0 HZ, ArH), 7.27 (d, 1H, J = 7.2 Hz, ArH), 7.16 (d, 2H, J = 9.0 Hz, ArH), 6.93 (d, 3H, J  = 
7.8 Hz, ArH), 4.16 (t, 2H, J = 5.9 Hz, CH2), 4.03 (t, 2H, J = 5.9 Hz, CH2), 1.89 (m, 4H, CH2); 
13C NMR (DMSO, 100MHZ) δ 165.0, 163.3, 158.9, 130.5, 129.8, 120.7, 119.6, 115.1, 114.7, 
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68.1, 67.2, 25.6, 25.5; νmax (Nujol) /cm-1 3288 (N-H), 1656 (C=N-H), 1604 (Ar), 1506 (Ar), 
1234 (C-O-C); m/z (ESP) 285 ([M+H]+), found 285.1603, C17H24N2O2 requires 285.1599; 
anal. Found C 59.50, H 6.75, N 8.33, C17H23N2O3Cl requires C 60.26, H 6.84, N 8.27. 
 
4-(5-(p-Tolyloxy)pentyloxy)benzonitrile  
 
 
Sodium (0.12 g, 5.22 mmol) was added portionwise to anhydrous ethanol (4.0 mL) and 
dissolved under a nitrogen atmosphere. To this a solution of 4-cyanophenol (0.57 g, 4.79 
mmol) dissolved in anhydrous ethanol (4.0 mL) was added followed by dropwise addition of 
1,5-dibromopentane (0.65 mL, 4.79 mmol). The reaction mixture was allowed to stir at reflux 
and monitored by TLC. After consumption of 4-cyanophenol the reaction mixture was cooled 
to room temperature. In a separate flask, sodium (0.57 g, 4,79 mmol) was added portionwise 
to anhydrous EtOH (4.0 ml) with stirring under nitrogen. To this, a solution of p-cresol (0.5 
ml, 4.79 mmol) in anhydrous EtOH (4.0 ml) was added and stirred for 10 minutes.  This 
mixture was added dropwise to the cooled mixture and stirred under reflux for 3 days after 
which the mixture was cooled, filtered and the solid washed with water and dried under 
vacuum.  Purification by column chromatography eluting with DCM: hexane (8:2) gave the 
desired compound as a white solid(1.02 g, 72%). Mp 133°C; 1H NMR (CDCl3, 400MHz) δ 
7.57 (d, 2H, J = 9 Hz, ArH), 7.07 (d, 2H, J = 8.6 Hz, ArH), 6.93 (d, 2H, J = 9.0 Hz, ArH), 6.79 
(d, 2H, J = 8.6 Hz, ArH) 4.02 (t, 2H, J = 6.4 Hz, CH2) 3.96 (t, 2H, J = 6.4 Hz, CH2), 2.28 (s, 
3H, CH3), 1.86 (m, 4H, CH2), 1.64 (m, 2H, CH2); 13C NMR (CDCl3, 100MHz) δ 162.7, 157.2, 
134.3, 130.3, 130.2, 115.5, 114.7, 104.1, 68.5, 68.0, 29.4, 29.1, 23.0, 20.8; νmax (Nujol) /cm-1 
3322 (C-O-C), 3031 (Ar-H), 2921 (C-H), 2223 (C≡N), 1602 (Ar), 1506 (Ar), 1234 (C-O-C); 
m/z (CI) 313 ([M+NH4]+), found 313.19092, C19H25N2O2 requires 313.19162; anal. Found C 
77.19, H 7.13, N 5.02, C19H21NO2 requires C 77.26, H 7.17, N 4.74. 
 
4-(5-(p-tolyloxy)pentyyloxy)benzimidamide hydrochloride hydrate (Compound 
CHI/1/72/1)  
 
 
 
4-(5-(p-Tolyloxy)pentyloxy)benzonitrile (0.27 g, 0.91 mmol) was dissolved in a mixture of 
anhydrous benzene (100 mL) and anhydrous ethanol (1.60 mL), cooled to 0 oC and 
saturated with HCl gas. The mixture was sealed and allowed to stir at room temperature for 
3 days after which anhydrous Et2O (20 mL) was introduced and the mixture was allowed to 
stir for 10 minutes. The solids were filtered under nitrogen and dissolved in a mixture of 
anhydrous EtOH (20 mL) and EtOH.NH3 (20 mL). The mixture was heated overnight (50 °C), 
cooled to room temperature and reduced by half in vacuo. Ether (30 mL) was added to 
precipitate the solid which was filtered, washed and dried under vacuum. Purification by 
recrystallisation (2N HCl) gave the desired compound  as fine white needles (0.25 g, 75%). 
Mp 132°C; 1H NMR (DMSO, 400MHZ) δ 7.84 (d, 2H, J = 9.1 Hz, ArH), 7.15 (d, 2H, J = 9.1 
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Hz, ArH), 7.06 (d, 2H, J = 8.4 Hz, ArH), 6.80 (d, 2H, J = 8.4 Hz, ArH), 4.11 (t, 2H, J = 6.4 Hz, 
CH2), 3.93 (t, 2H, J = 6.4 Hz, CH2), 2.22 (s, 3H, CH3), 1.78 (m, 4H, CH2), 1.56 (m, 2H, CH2); 
13C NMR (DMSO, 100MHz) δ 165.0, 163.3, 158.9, 130.5, 130.1, 115.1, 114.5, 79.5, 79.3, 
79.0, 20.4; νmax (Nujol) /cm-1 3430 (NH), 3309 (C-O-C), 3093 (Ar-H), 1658 (C=N-H), 1606 
(Ar), 1508 (Ar), 1245 (C-O-C); m/z (ESP) 313 ([M+H]+), found 313.1916, C19H25N2O2 
requires 313.1907; anal. Found C 62.19, H 7.42, N 7.66, C19H27ClN2O3 requires C 62.20, H 
7.42, N 7.66. 
 
 
Synthesis of ER 1004 
 
4-bromobenzothioamide 
 
Br
H2N S
 
 
Triethylamine (3.8 mL) was added to a solution of 4-bromobenzonitrile (5 g, 27.5 mmol) in 
pyridine (17 mL). The solution was cooled to 10 oC and H2S (g) was bubbled through for 15 
min. The resulting green solution was allowed to stir overnight (17 h). Nitrogen was bubbled 
through for 1 h to remove any excess H2S. Water (27 mL) was added and the mixture was 
stirred for 10 min, a further portion of water (62 mL) was added and the pale yellow 
suspension left stirring overnight. The precipitate was filtered and rinsed with water to afford 
the title compound as bright yellow crystals (5.52 g, 93%). 1H NMR (d6-acetone, 400MHz) 
9.07 (bs, 1H, NH), 8.92 (s, 1H, NH), 7.94 (dd, 2H, J = 2.0, 6.5 Hz, ArH), 7.62 (dd, 2H, J = 
2.0, 6.5 Hz, ArH); 13C NMR (d6-acetone, 100MHz) 201.9, 140.2, 132.3, 130.4, 126.5; m/z 
(CI) 216 (100%, [M+]) 
 
2,4-bis(4-bromophenyl)thiazole 
 
S
N Br
Br
 
 
2,4'-dibromoacetophenone (1 g, 3.60 mmol) was added to a solution of 4-
bromobenzothioamide (777 mg, 3.60 mmol) in EtOH (15 mL) and warmed to 45 oC for 1 h. 
The mixture was cooled to room temperature and left for 30 min before filtering. The 
precipitate was washed with EtOH: water (3:1, 10 mL) and dried to afford the thiazole as a 
pale solid (1.33 g, 94%). 1H NMR (CDCl3, 250MHz) 7.89 (d, 2H, J = 8.5 Hz, ArH), 7.85 (d, 
2H, J = 8.5 Hz, ArH), 7.59 (d, 2H, J = 5.5 Hz, ArH), 7.56 (d, 2H, J = 5.5 Hz, ArH), 7.47 (s, 
1H, CH); m/z (CI) 396 (10%, [M+H]+). 
 
4,4'-(thiazole-2,4-diyl)dibenzonitrile 
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S
N CN
NC
 
 
A suspension of 2,4-bis(4-bromophenyl)thiazole (1 g, 2.53 mmol) and CuCN (906 mg, 10.12 
mmol) in anhydrous DMF (15 mL) were heated to reflux for 21 h. On cooling, the reaction 
mixture was poured into aqueous NH4OH (10%, 50 mL) and extracted with CHCl3 (100 mL). 
Both layers were filtered to remove the dark precipitate. The organic layer was washed with 
water (2 x 50 mL), brine (50 mL) and dried MgSO4. Removal of solvent gave a dark oily 
solid. Purification by column chromatography eluting with CHCl3, afforded the title compound 
as a pale solid (361 mg, 50%). 1H NMR (CDCl3, 400MHz) 8.15 (d, 2H, J = 8.5 Hz, ArH), 8.11 
(m, 2H, ArH), 7.77 (d, 2H, J = 8.5 Hz, ArH), 7.73 (t, 2H, J = 3.0 Hz, ArH), 7.26 (s, 1H, CH); 
13C NMR (CDCl3, 100MHz) 166.5, 137.4, 133.2, 130.1, 127.3, 119.1, 117.1, 114.2, 112.4; 
m/z (CI) 288 (100 %, [M+H]+). 
 
4,4'-(thiazole-2,4-diyl)dibenzimidamide (ER1004) 
 
S
N
NH
NH2 .2 TFA
NH
H2N
 
 
The Garigipati Reaction is a little known reaction which effects the conversion of hindered 
nitriles to unsubstituted amidines in a mild and effective manner 2, 3.  This is an efficient one 
step transformation involving direct nucleophilic addition of an amine to a nitrile, affording the 
corresponding amidine (Scheme 1).  
 
 
S
N
NC
CN
S
N
NH
NH
NH2
H2NMeAl(Cl)NH2
Toluene, 80oC
 
Scheme 1. 
 
 
The alkylchloroaluminium amides are effectively generated from trimethyl aluminium and 
ammonium chloride and the intermediate aluminium complex is easily hydrolyzed by water 
adsorbed on silica gel (Scheme 2). 
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NH3.HCl + (CH3)3Al CH3Al(Cl)NH2 + CH4
RCN
CH3Al(Cl)NR'R''
Toluene
80oC R
N Al
Me
Cl
NR'R''
H2O
R
NH
NH2SiO2
 
 
 
Scheme 2. 
 
The freshly prepared alkylchloroaluminum reagents (4 mL, 0.67 M, 2.7 mmol) were added to 
4,4'-(thiazole-2,4-diyl)dibenzonitrile (78 mg, 0.27 mmol) in anhydrous toluene (1 mL) and 
heated to 80 oC overnight under nitrogen. On cooling, the aluminium complex was 
decomposed by pouring into a slurry of silica gel (2 g) in CHCl3. The mixture was stirred for 5 
min before filtering, the filter cake was washed with MeOH (20 mL). Removal of solvent gave 
the crude amidine as a pale solid in quantitative yield. The crude product (100 mg) was 
purified by reverse phase HPLC using a YMC-pack ODS-A column (250 x 20 mm I.D, 5 µM) 
eluting with CH3CN: Water 0.1% TFA (20-80 % gradient over 20 min). Removal of solvent 
afforded the desired compound as an off-white solid (38 mg, 22%).  Mp 271-272 oC; 1H NMR 
(DMSO, 400MHz) 9.32 (bs, 6H, NH & NH2), 8.54 (s, 1H, CH),  8.25 (d, 2H, J = 8.5 Hz, ArH), 
8.22 (d, 2H, J = 8.5 Hz, ArH), 7.92 (d, 2H, J = 8.5 Hz, ArH), 7.90 (d, 2H, J = 8.5 Hz, ArH); 
13C NMR (DMSO, 100MHz)  165.5, 165.4, 154.4, 138.7, 137.4, 129.6, 129.2, 127.9, 126.9, 
126.8, 119.6; m/z (ES) 322 (88 % [M+H]+); Found (ES) 322.1121 C17H16N5S requires 
322.1126; anal. Found C 46.05, H 3.10, N 12.44, S 5.77, C21H18N5O4F6S requires C 45.91, H 
3.12, N 12.74, S 5.83.   
 
References 
 
 
1. R. R. Tidwell, S. K. Jones, J. D. Geratz, K. A. Ohemeng, M. Cory and J. E. 
Hall, Journal of Medicinal Chemistry, 1990, 33, 1252-1257. 
2. Moss, R.A., et al., Conversion of Obstinate Nitriles to Amidines by Garigipatis 
Reaction. Tetrahedron Letters, 1995. 36(48): p. 8761-8764. 
3. Garigipati, R.S., An Efficient Conversion of Nitriles to Amidines. Tetrahedron 
Letters, 1990. 31(14): p. 1969-1972. 
 
 
  
.CC-BY 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted March 10, 2020. . https://doi.org/10.1101/2020.03.08.982751doi: bioRxiv preprint 
24 
 
Chemistry of new compounds from David Boykin laboratory. 
 
 
General procedure for conversion of nitriles into amidine hydrochlorides (Method A). 
To a cold and stirred suspension of the nitrile or dinitrile (0.001 mol) in 15 ml dry THF was 
added 6.0 ml, (0.006 mol) LiN(TMS)2 (1 M in THF), stirred for 24 h, cooled, acidified 
carefully with saturated ethanolic-HCl, the precipitated white solid stirred for 2 h, solvent 
removed under reduced pressure, diluted with ether, filtered. The collected solid was added to 
10 ml ice water, basified with 2M NaOH, the precipitate was filtered, washed with water and 
air dried. The solid was suspended in anhydrous ethanol (15 ml) and 5 ml saturated ethanolic-
HCl and stirred for 6 h, ethanol was distilled off, triturated with dry ether and filtered. The 
solid was dried under reduced pressure at 800C for 12 h to yield (70-75%) amidine 
hydrochloride. 
 
General procedure for conversion of nitriles into amidine hydrochlorides (Method B). 
A suspension of the nitrile or dinitile (0.001 mole) in 20 ml saturated ethanol-HCl was stirred 
for 4 days in a closed stoppered flask, followed by precipitation with anhydrous ether. The 
precipitated light yellow solid imidate ester dihydrochloride was filtered and dried under 
reduced pressure for 3 h to yield (65% -70%) amidine hydrochloride. The imidate ester 
dihydrochloride (0.0005 mole) in 20 ml anhydrous ethanol was saturated with ammonia(g)  
or 0.03 equivalents of ethylene diamine stirred in ethanol (at reflux) for 12 h, solvent 
removed, 20 ml ice water added, basified to pH 10 with aqueous 2N NaOH, filtered, and 
washed with water. The precipitated solid was dried in air, suspended in 10 ml of saturated 
ethanolic-HCl, and stirred for 2 h. The solvent removed, dry ether 20 ml added, filtered, 
washed with ether and dried under reduced pressure for 12 h. The product amidine 
hydrochloride was obtained as yellow solid 60-66% yield. 
 
4-(5-(4-methoxyphenyl) furan-2-yl) benzimidamide hydrochloride (DB 607) 
A mixture of 5-(4-cyanophenyl)-2-bromo furan1 (1.23 g, 0.005 mole) and 4-methoxyphenyl 
boronic acid  (0.93 g, 0.006 mole) in 75 ml dioxane under nitrogen was added K2CO3 (1.38 g, 
0.01 mole, in  5 ml H2O), followed by  Pd(PPh3)4  0.12 g (0.0001 mole) and the solution was 
heated under reflux for 12-24 h (tlc monitored). The solvent was removed under reduced 
pressure, solid filtered, washed with hexane and dried in air. The solid was suspended in 
DCM  (100 ml), filtered through celite, concentrated under reduced pressure, triturated with 
ether: hexane  (2:1),  and filtered to yield 4-(5-(4-methoxyphenyl)furan-2-yl)benzonitrile as a 
yellow brown solid 0.76 g (74%)  mp 250-2 °C dec ; 1H NMR (DMSO-d6): 7.94 (d, 2H, J= 
10.4 Hz), 7.85 (d, 2H, J= 10.4 Hz), 7.78 (d, 2H, J= 10.8 Hz), 7.28 (d, 1H, J= 4.4 Hz), 7.02 (d, 
2H, J= 10.8 Hz), 6.97 (d, 1H, J= 4.4 Hz), 3.81 (s, 3H); 13C NMR (DMSO-d6): 159.3, 154.5, 
150.0, 134.1, 132.9, 125.4, 123.5, 122.5, 119.0, 114.4, 111.8, 108.8, 106.9, 55.2; MS: 
HRMS-ESI-POS: Calcd. for C18H14NO2 m/z 276.1024 (M++1), found m/z 276.1021. 
The amidine hydrochloride was obtained as yellow solid (Method A) 0.24 g (74%) ; mp 
>318°C dec ; 1H NMR (DMSO-d6): 9.41 (brs, 2H), 9.1 (brs, 2H), 8.01 (d, 2H, J= 8.4 Hz), 
7.92 (d, 2H, J= 8.4 Hz), 7.82 (d, 2H, J= 8.4 Hz), 7.324 (d, 1H, J= 3.6 Hz), 7.04 (d, 2H), 7.02 
(d, 1H, J= 3.6 Hz), 3.82(s, #H); 13C NMR (DMSO-d6): 164.9, 159.2, 154.3, 150.2, 134.8, 
128.8, 125.5, 125.4, 123.0, 122.5, 114.4, 111.4, 106.8, 55.2; ; MS: HRMS-ESI-POS.: Calcd. 
for C18H17N2O2 m/z 293.1289 (M++1), found m/z 293.1274; Anal. calcd. for C18H16N2O2-
HCl: C, 65.75; H, 5.21; N, 8.52; Found: C, 65.78; H, 5.23; N, 8.44. 
 
4,4'-(thiophene-2,4-diyl) dibenzimidamide dihydrochloride (DB 1077) 
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A mixture of 2, 4-dibromothiophene 1.21 g (0.005 mole), 4-cyanophenylboronic acid 1.75 g 
(0.012 mole) following procedure for DB 607, yielded 2,4-(4-cyanophenyl)thiophene as a 
yellow solid, 0.86 g (72%)  mp >220°C dec ; 1H NMR (CDCl3): 7.75-7.21 (m, 8H), 7.71 (d, 
1H, J= 1.2 Hz), 7.64 (d, 1H, J= 1.2 Hz); 13C NMR (CDCl3): 143.6, 141.6, 139.4, 138.0, 
132.9, 132.8, 126.8, 126.1, 123.8, 123.7, 118.8, 118.6, 111.3, 111.1; MS: HRMS-ESI-POS: 
Calcd. for C14H11N2S m/z 239.0642 (M++1), found m/z 239.0639.   
The diamidine hydrochloride was obtained as yellow solid (Method A) 0.32 g (74%)  
mp>300°C dec ; 1H NMR (DMSO-d6): 9.55 (brs, 2H), 9.54 (brs, 2H), 9.31 (brs, 4H), 8.42 (s, 
1H), 8.32 (s, 1H), 8.09 (d, 2H, J= 8.4 Hz), 8.03-7.97 (m, 6H); 13C NMR (DMSO-d6): 164.9, 
164.8, 142.5, 140.9, 139.5, 138.3, 129.1, 128.8, 126.6, 126.3, 126.2, 125.4, 125.0, 124.8; MS: 
HRMS-ESI-POS.: Calcd. for C18H18N4S m/z 161.0626 (M++2)/2, found m/z 161.0621; Anal. 
calcd. for C18H16N2S-2HCl-2H2O: C, 50.35; H, 5.16; N, 13.05; Found: C, 50.52; H, 5.23; N, 
13.22. 
 
3,3'-(furan-2,5-diyl bis (4,1-phenylene)) dipropanimidamide dihydrochloride (DB 1061) 
To a mixture of 4-bromophenyl propionitrile 0.63 g (0.003 mole) and 2, 5-bis 
(tributylstannyl) furan in 30 ml anhydrous dioxane under nitrogen was added Pd(PPh3)4  0.14 
g (0.00012 mole) and the solution was heated under reflux for 12 h (tlc monitored). The 
solvent was removed under reduced pressure, the solid was filtered, washed with hexane and 
dried in air. The solid was suspended in DCM  (50 ml), stirred 2 h with 20 ml 10% KF 
(aqueous), the organic layer separated, filtered through celite  dried over  anhydrous MgSO4, 
filtered, concentrated,  triturated with hexane and the solid filtered was filtered to yield 0.34 g 
(70%) of 3,3'-(furan-2,5-diylbis(4,1-phenylene))dipropanenitrile as a yellow solid   mp 120-
2°C dec;  1H NMR (CDCl3): 7.73 (d, 4H, J= 8.4 Hz), 7.30 (d, 4H, J= 8.4 Hz),7.28 (s, 2H), 3.0 
(t, 4H, J= 7.6 Hz), 2.66 (t, 4H, J= 7.6 Hz); 13C NMR (CDCl3): 153.2, 137.2, 130.0, 128.9, 
124.4, 119.2, 107.2, 31.5, 19.5; MS: HRMS-ESI-POS: Calcd. for C22H18N2ONa m/z 
349.1317 (M++Na), found m/z  349.1332. 
The diamidine dihydrochloride was obtained using Method B: 0.14 g (60%)  mp>300°C dec ; 
1H NMR (DMSO-d6): 9.13 (brs, 4H), 8.74 (brs, 4H), 7.64 (d, 4H, J= 8.4 Hz), 7.49 (s, 2H), 
7.33 (d, 4H, J=8.4 Hz), 3.0 (t, 4H, J= 7.2 Hz), 2.74 (d, 4H, J= 7.2 Hz); 13C NMR (DMSO-d6): 
170.6, 142.7, 139.4, 132.4, 129.6, 125.8, 125.2, 33.7, 32.03; MS: HRMS-ESI-POS: Calcd. 
for C22H26N4O m/z 181.1053 (M++2)/2, found m/z 181.1048; Anal. calc. for C22H24N4O-
2HCl-2H2O: C, 56.29; H, 6.44; N, 11.93; Found: C, 56.35; H, 6.54; N, 11.86. 
 
2,5-bis(4-(2-(4,5-dihydro-1H-imidazol-2-yl) ethyl) phenyl) furan dihydrochloride (DB 
1062) 
Similarly, 0.245 g (0.005 mole) of the above imidate ester  in 20 ml of anhydrous ethanol was 
allowed to react under reflux (12 h) with 0.06 g (0.0015 mole) ethylene diamine. The solvent 
was removed under reduced pressure, diluted with water,  solid was filtered, dried and 
converted to dihydrochloride using ethanolic-HCl to yield a yellow solid, 0.15 (62%), mp 
>325 oC, H NMR (DMSO-d6): 8.29 (br, 4H), 8.74 (brs, 4H), 7.77 (d, 4H, J= 8.4 Hz), 7.34 (s, 
2H), 7.05 (d, 4H, J=8.4 Hz), 3.0 (t, 4H, J= 7.2 Hz), 2.74 (d, 4H, J= 7.2 Hz); 13C NMR 
(DMSO-d6): 170.2, 152.4, 138.5, 128.8, 128.6, 123.6, 108.0, 44.0, 30.5, 27.4; MS: HRMS-
ESI-POS: Calcd. for C26H30N4O m/z 207.1209 (M++2)/2, found m/z 207.1203; Anal. calc. for 
C26H28N4O-2HCl-2.75H2O: C, 58.37; H, 6.68; N, 10.47; Found: C, 58.45; H, 6.54; N, 10.63. 
 
3,3'-(thiophene-2,5-diylbis(4,1-phenylene)) dipropanimidamide dihydrochloride (DB 
1063) 
 The dinitrile, 3,3'-(thiophene-2,5-diylbis(4,1-phenylene))dipropanenitrile, was prepared as 
described for DB1061 yielding a yellow solid 0.77 g (75%); mp 124-60C dec.;1H NMR 
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(CDCl3): 7.62 (d, 4H, J= 8.0 Hz), 7.29 (d, 4H, J= 8.0 Hz),7.28 (s, 2H), 3.0 (t, 4H, J= 7.2 Hz), 
2.66 (t, 4H, J= 7.2 Hz); 13C NMR (CDCl3): 143.3, 137.5, 133.5, 129.1, 126.2, 124.2, 119.2, 
31.4, 19.4;  MS: HRMS-ESI-POS: Calc. for C22H18N2SNa m/z 365.1088 (M++Na), found m/z  
365.1089. 
Similarly following the DB 1061 procedure the diamidine dihydrochloride was obtained as a 
yellow solid 0.16 g (66%), mp >2800C dec;  1H NMR (DMSO-d6): 9.19 (brs, 4H), 8.77 (brs, 
4H), 7.64 (d, 4H, J= 8.0 Hz), 7.51 (s, 2H), 7.33 (d, 4H, J=804 Hz), 2.99 (t, 4H, J= 8.4 Hz), 
2.73 (d, 4H, J= 8.4 Hz); 13C NMR (DMSO-d6):170.0, 142.2, 138.9, 131.9, 129.1, 125.3, 
124.7, 33.2, 31.6; MS: HRMS-ESI-POS: Calcd. for C22H26N4S m/z 189.0939 (M++2)/2, 
found m/z 189.0931; Anal. calcd. for C22H24N4S-2HCl-1.5H2O: C, 55.45; H, 6.13; N, 11.76; 
Found: C, 55.52; H, 6.34; N, 11.63.  
 
2, 5-bis(4-(2-(4,5-dihydro-1H-imidazol-2-yl) ethyl) phenyl) thiophene dihydrochloride 
(DB 1064) 
Similarly following the procedure for DB1062 the diamidine dihydrochloride was obtained as 
a yellow solid, 0.17 g (62%); mp >225°C dec.;  1H NMR (DMSO-d6): 10.19 (s, 4H), 7.63 (d, 
4H, J=7.6 Hz), 7.5 (s, 2H), 7.30 (d, 4H, J= 7.6 Hz), 3.78 (s, 8H),2.97 (t, 4H, J= 6.4 Hz), 
2.81(t, 4H, J= 6.4 Hz); 13C NMR (DMSO-d6): 170.2, 140.2, 138.9, 131.9, 129.1, 125.4, 
124.8, 44.1, 30.6, 27.4; MS: HRMS-ESI-POS: Calcd. for C26H29N4S m/z 429.2113 (M++1), 
found m/z 429.2109; Anal. calcd. for C26H28N4S-2HCl-3.0H2O: C, 56.21; H, 6.53; N, 10.08; 
Found: C, 56.34; H, 6.61; N, 10.24. 
 
4-(5-(1-methyl-1H-benzo[d]imidazol-2-yl) furan-2-yl) benzimidamide dihydrochloride 
(DB 960) 
To a stirred solution of 5-(4-cyanophenyl) furan-2-aldehyde2 1.23 g (0.005 mole), 1-amino-2-
N-(methylamino) benzene 0.61 g (0.005 mol) in 20 ml dry DMF under N2 was added sodium 
metabisulfite 0.95 (0.005 mol) and the mixture was heated at 130°C for 12 h (tlc monitored). 
The solvent was removed, the residue was triturated with cold water, separated solid was 
filtered, washed with water and air dried. The solid was stirred with 1:1 mixture of DCM-
ether, filtered and dried in vac at 70°C for 4 h to give the nitrile, 4-(5-(1-methyl-1H-
benzo[d]imidazol-2-yl)furan-2-yl)benzonitrile, as a yellow brown solid, 1.1 g (72%), mp 
>290°C dec ; 1H NMR (DMSO-d6): 8.03 (d, 2H, J= 8.4 Hz), 7.92 (d, 2H, J= 8.4 Hz), 7.69-
7.63 (m, 2H), 7.46 (d, 1H, J= 3.6 Hz), 7.40 (d, 1H, J= 3.6 Hz), 7.34-7.23 (m, 2H), 4.13 (s, 
3H); 13C NMR (DMSO-d6): 152.4, 145.9, 143.2, 142.4, 136.0, 133.2, 132.9, 124.2, 122.7, 
122.2, 118.9, 118.5, 114.7, 111.1, 110.2, 109.9, 31.4; MS: HRMS-ESI-POS: Calcd. for 
C19H14N3O m/z 300.1136 (M++1), found m/z 300.1132. 
The amidine hydrochloride was obtained as yellow solid (Method B) 0.3 g (78%); mp 
>300°C dec; 1H NMR (DMSO-d6): 8.09 (d, 2H, J= 8.7 Hz), 7.90  (d, 2H, J= 8.7 Hz), 7.78-
7.70 (m, 2H), 7.61 (d, 1H, J= 3.9 Hz), 7.48-7.42 (m, 2H), 7.45 (d, 1H, J= 3.9 Hz), 4.13 (s, 
1H); 13C NMR (DMSO-d6): 165.5, 155.6, 141.5, 141.3, 135.3, 134.8, 133.9, 129.5, 128.0, 
126.0, 125.8, 125.5, 119.6, 116.4, 112.4, 112.0, 32.9; MS: HRMS-ESI-POS: Calcd. for 
C19H18N4O m/z 159.0740 (M++2)/2, found m/z 159.0733; Anal. calcd. for C19H16N4O-2HCl-
1H2O: C, 56.02; H, 4.94; N, 13.76; Found: C, 56.18; H, 4.91; N, 13.51. 
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